hannah a. valantine, m.d., m.r.c.p. - workforce … chelsea college, london university, uk b.sc.,...

CURRICULUM VITAE

NAME: HANNAH A. VALANTINE, M.D., M.R.C.P., F.A.C.C. Current Position: Chief Officer for Scientific Workforce Diversity Senior Investigator Office of the Director Laboratory of Transplantation Genomics National Institutes of Health National Heart, Blood, and Lung Institute 1 Center Drive, Building 1, Room 316 National Institutes of Health Bethesda, MD 20892 50 South Drive Main: (301) 451-4296 Bethesda, MD 20814 [email protected] Chair, Genome Research Alliance for Transplantation (GRAfT) Prior Position: Senior Associate Dean - Diversity and Leadership Director - Heart Transplantation Research Professor - Medicine Stanford University School of Medicine

EDUCATION 1970-73 Chelsea College, London University, UK B.Sc., Biochemistry 1973-78 St. George's Hospital, London University, UK M.B.B.S. 1977 University of Hong Kong Medical School Elective Surgery 1981 Royal College of Physicians, UK M.R.C.P (ABIM equivalent) Jan 1988 London University, UK M.D. (PhD. Equivalent)

POSTGRADUATE TRAINING AND FELLOWSHIPS:

1978-79 House Physician, St. George's Hospital, London, UK Professor T. Pilkington: General medicine, diabetes, and endocrinology 1979 House Surgeon, Kingston Hospital, Surrey, UK Mr. G.H. Farrington: General adult and pediatric surgery 1979-80 Senior House Officer in General Medicine, Kingston Hospital, Surrey, UK Dr. I. Strickland: General medicine and gastroenterology Dr. W. Medd: General medicine and diabetes 1981 Senior House Officer/Registrar in General Medicine and Intensive Care St. George's Hospital Medical School, London, UK Dr. D.E. Bennett 1981-82 Senior House Officer in Cardiology, Brompton Hospital, London, UK Drs. R. Gibson, D. Gibson, and M. Honey 1982 Senior House Officer in Renal Medicine, Guy's Hospital, London, UK Professor S. Cameron, Drs. C. Ogg and G. Williams 1983-84 Registrar in Cardiology and General Medicine, Hammersmith Hospital, London, UK Professors J. Goodwin and A. Masseri; Drs. C. Oakley and C. Hallidie-Smith 1985 Research Registrar in Cardiovascular Medicine, St. George's Hospital Medical School, London,

UK, Dr. D.E. Bennett, Professor K. Saunders 1985-86 Postdoctoral Fellow in Cardiology, Stanford University School of Medicine - Dr. R. Popp 1987-88 Clinical Assistant Professor, Cardiology Division, Stanford University School of Medicine

mailto:[email protected]

Hannah A. Valantine, M.D., M.R.C.P., F.A.C.C.

PRINCIPLE ACADEMIC POSITIONS & APPOINTMENTS 1988 Acting Assistant Professor of Medicine, Cardiology Division, Stanford, CA 1989-96 Assistant Professor of Medicine, Div. Cardiovascular Medicine, Stanford, CA 1996-00 Associate Professor of Medicine, Division of Cardiovascular Medicine, Stanford, CA 2000- Professor of Medicine, Division of Cardiovascular Medicine, Stanford, CA 2004-13 Senior Associate Dean for Diversity and Leadership- Stanford University School of Medicine 2008-13 Diversity and Career Development Program Leader - Clinical and Translational Science Award CERTIFICATION & LICENSES CERTIFICATIONS June 1980 M.R.C.P., Part I Feb. 1981 M.R.C.P., Part II July 1985 Foreign Medical Graduate Examination in the Medical Sciences (FMGEMS), USA Dec. 1985 Federation of Licensure Examination (FLEX), USA June 2006 Executive Leadership in Academic Medicine (ELAM) LICENSES UK Lis. #: 24431 California Lis. #: A45659 DEA#: BV1866966 HONORS AND AWARDS 1976: President of Medical School Student Union, St. George's Hospital, London University, UK 1977: Sir Charles Clarke Prize for the student contributing the most to the life of the school St. George's Hospital, London, UK 1986: Postdoctoral Fellowship Award, Stanford University Cardiology 1990: First Place Poster Award - International Society of Heart and Lung Transplantation 1995: Mentor Award - Black Community Services Center- Stanford University 2001: Excellence in Health Care Award - America’s Outstanding Physicians - Black Enterprises 2002: Best Doctor in America 2006: Exceptional Contributions to Education in Medicine - Stanford University Department of Medicine 2009: Seventh Annual Diversity Visiting Professor – Johns Hopkins Department of Medicine 2010: Pathfinder Award for Research for diversity in biomedical research workforce – NIH Director 2013: Member – National Academies Panel to review the science of team science 2013: President's Awards for Excellence Through Diversity – Stanford University 2014: Women of Influence – Silicon Valley

KEYWORDS/AREAS OF INTEREST CLINICAL RESEARCH: Heart transplantation pathophysiology of acute and chronic rejection; mechanisms of cardiac allograft vasculopathy and role of cytomegalovirus; echocardiographic markers of diastolic dysfunction for non-invasive diagnosis of acute rejection; genomic approaches to rejection surveillance including gene expression profiling and donor DNA sequencing. GENERAL CARDIOLOGY: Heart disease in women DIVERSITY AND LEADERSHIP: Diversity and faculty career development in academic medicine; faculty mentoring programs; unconscious bias and stereotype threat as barriers to faculty career advancement for women.


CLINICAL, TEACHING, MENTORING AND RESEARCH RESPONSIBILITIES Fifty percent of my time is spent on these activities CLINICAL AND PATIENT CARE RESPONSIBILITIES Co-Director of Post-Transplant Cardiac Transplant Service: Outpatient management; inpatient care two months per year; analysis of all echocardiographic studies in heart transplant patients – two half-day sessions per week TEACHING RESPONSIBILITES Teaching of medical residents in outpatient clinic and inpatient services Teaching of cardiology fellows in outpatient, inpatient, and cardiac transplant echo services Lecture to undergraduate courses in human physiology: 1994: Cardiac Transplantation 1995: Cardiac Rhythm 1996: Acceptance and rejection of hearts: Pre-Med students - (featured in Herb Caen’s column, SF Chronicle) 1997: Towards Healthier Hearts for women: women’s health core curriculum 2002: Cardiovascular Physiology Course: Heart Transplantation Teaching transplant post doctoral fellows on clinical concepts as they relate to transplantation medicine: a) Transplant immunology b) Cardiac function focusing on echocardiographic measures of cardiac function c) Allograft vasculopathy and intracoronary ultrasound d) Mechanisms of atherosclerosis, focusing on antigen-independent pathways. MENTORING HISTORY – MENTEES AND CURRENT POSITIONS

Trainee Category Name

Institution Date & Type of Degree Awarded

Training Period

Training & mentoring received

Title of Research Project

Publication Current Institution/ Position

HIGH SCHOOL

Cooke, Margaret Castilleja 2003

2000-01 Clinical research

Leucopenia - marker of CMV infection

Transplantation 2006 15; 82: 1419-24

UCSF Medical Student

Amos, Tope Castilleja 2005


Stanford University Medical Student

Ransohoff, Katherine

Castilleja 2006

2004-06 Clinical patient care

N/A N/A Harvard University

UNDERGRADUATE

Kemna, Mariska

Univ Groningen, Netherlands 1996

1992-93 Clinical Research

Metabolic risk factors in heart transplant

Am Heart J. 1994 Jul;128(1):68-72.

Stanford Pediatric Residency


MD patients

Mammo, Dagem

Stanford 2011 BS


Transplant Vasculopathy

None Stanford University School of Medicine

Okogba, Janet Stanford 2010

BS 2008 Clinical &

Echo-cardiography

N/A None Research fellow Cooke Lab -Stanford

PREDOCTORAL

Panchal, Shyam

Stanford 1997 BS Boston U 2004 MA

1998-02 Laboratory and clinical research

Rodent models of transplant vascular disease Effects of CMV in heart patients

Clin Tran. 2002 16(3) JHLT 2002: 21 (6) JHLT 2002: 21 (9) Pediatr Radiol. 2001 31(12) Circulation. 2001 104(21) Circulation 2004 109(4)

Research Assoc. Cooke Lab Stanford

Lee, Julia

UC Davis 2003 BS

2003-04 Laboratory and clinical research

Role of CMV in transplant vasculopathy

None Research Assoc. Law Lab Orthopedic Surgery

Caohuu, Tuyen

UC Davis 2005 BS


Role of CMV in transplant vasculopathy

None Medical Student University Florida

Link, Ryan

UC Berkeley 2007 BA


Multi-center Clinical trials

None Genentech Research Associate

POSTDOCTORAL

Zhang, Lunan Shandong Medical Univ. 1987

1989-91 Basic Research

Cytokines as mediators

None Research Assoc. Harvard


MD, PhD of allograft dysfunction

University

Dong, Chun-Ming

Shandong Medical Univ. 1990 MD


Cytokines as mediators of allograft dysfunction

Transplant Proc. 1994 Oct;26(5):2852-3

Sr. Research Assoc. Univ. British Columbia

Johnson, Frances

Univ. Washington 1988 MD

1993-94 Basic & Clinical Research

Cytokines as mediators of allograft dysfunction

Transplant Proc. 1994 Oct;26(5):2852-3

Assoc. Prof. University Iowa

Gullestad, Lars

Univ of Rikshospitalet 1985 MD, PhD


Mechanisms of cardiac allograft failure

Circulation. 1996 Clin Transp. 1997:11 JHLTransp. 1997

Professor, Oslo University Hospital Finland

Ross, Heather

Univ. Dalhousie 1988 MD

1994 - 1996

Basic & Clinical Research

Granzyme and perforin as mediators of allograft dysfunction and rejection

Transplantation. 1995:60 Transplantation. 1995 60(12) Circulation 1996: 94 Clin Transp. 1997:11 JHLTransp. 1997 Circulation. 1998: 97

Professor Co-director multi-organ transplant Center University of Toronto

Hoang, Khanh

UCSF 1992 MD


Role of diabetes in transplant vascular disease

Clin Transp. 1997: 11 Circulation. 1998: 97

Staff Physician, North Texas Heart Center

Gianetti, Nadia

Univ. McGill 1991 MD


Effects mycophenolate on transplant rejection

Clin Tran. 2002 16(3)

Director heart Transplantation McGill university

Parekh, Hemal University Cincinnati, 1992 MD


Role of mycophenolate blood levels in monitoring acute

Clin Tran. 2002 16(3) Am J Transplant. 2007: 7(10)

Assoc. Director Heart Failure Kaiser Permanente San Jose, CA


rejection

Cantin, Bernard Univ. Laval.

1995 MD

2000-2001

Clinical and basic research

Metabolic syndrome in transplant vascular disease

JHLT 2002: 21(6) JHLT 2002: 21(9) Clin Tranpl: 2002: 16(3) Transpl. Proc. 2002: 34 Circulation: 2001:104 J HLT 2003: 22 (7) Transplantation. 2003: 76

Medical Director Heart Transplant Univ. Quebec

Kwok, Bernard National University Singapore 1996 Master Medicine

2000-2001

Clinical Research

Immune suppression and clinical outcomes after heart transplantation

Clin Tranpl: 2002: 16(3) Transpl. Proc. 2002: 34 Transplantation. 2003: 76 J HLT 2003: 22 (7) J HLT 2003: 22 (7) J HLT 2004: 23(2)

Consultant Cardiologist Mount Elizabeth Medical Centre & National Heart Centre of Singapore

Chan, Michael University Hong Kong 1987 MBBS

2001-2002

Clinical Research

Outcomes after heart transplantation

J Am Coll Card. 2004:43 J HLT 2004: 23(2) Transplantation. 2003: 76 J HLT 2003: 22 (7) Transpl. Proc. 2002: 34 JHLT. 2001: 20(7)

Cardiology Consultant Edmonton

Kato, Tomoko University

Osaka 1990 MD



J Am Coll Cardiol. 2004:43 JHLT. 2001: 20(7)

Cardiologist & Clinical Investigator National Cardiovascular Center, Osaka

Zhu, Denning Guangzhou Med College Guangdong China


Optimizing Animal models of heart

JHLT 2002: 21(6) JHLT 2002: 21(9) Pediatr Radiol: 2001 31

Internist New York University Medical


1989, MD transplantation

Circulation: 2001:104

center

Potena, Luciano

University Bologna 1990 MD

2002-04 Clinical & Translational Research

Role of CMV in cardiac allograft vasculopathy

Transplantation. 2008: 85 Endo. Metab. Clin. 2007 Curr Op. Infect Dis. 2007 Transplantation. 2007: 83 J Clin Microbiol. 2007: 45 J HLT. 2007: 26(4) G Ital Cardiol. 2007: 8 Transplantation. 2006: 82 Circulation. 2006: 10 Transplantation. 2004: 78

Co-director heart transplantation University Bologna

Holweg, Cecile

Erasmus Univ. Rotterdam 2003 PhD


Mechanisms of CMV induced cardiac allograft vasculopathy

Transplantation. 2006: 82 J Clin Microbiol. 2007: 45 Transplantation. 2004: 78

Sen. Research Scientist Genentech

Ananthram, Manjula

Kasturba Medical College 1992 MD


Not Relevant

None Good Samaritan Cardiology Baltimore

Kuppahally, Suman

Government Medical College Nagpur India 1996 MBBS

2004-05 Clinical patient care & research


J HLT. 2009: 28(4). Am J Transplant. 2007: 7 Am J Transplant. 2006: 6 J HLT. 2006 25(1)

Cardiology Private Practice San Jose, CA

Haddad, Francois Univ. Montreal 1998 MD

2006-07 Clinical patient care & research


J HLT. 2010:29(3) J HLT. 2009:28(4) Am J Transp. 2007 7(10)

Clinical Assistant Professor, Medicine

http://cvmedicine.stanford.edu/


J HLT. 2007 26(1) J HLT. 2006 25(11)

Cardiovascular Medicine

Almedrai, Jesus

Univ. Philippines College Of Medicine 1992 MD


None None Asst. Professor Temple University Hospital

Parent, Marie-Claude

Univ. Quebec 1992

2009-10 2010-11

Clinical care Research

MRI monitoring of cardiac function & CAD in transplant recipients

None Research Fellow Stanford Cardiac Imaging Mentors - Drs. Yang & Valantine

Skhiri, Medhi

Necker-Enfants Malades Paris 1995 MD


None None Research Fellow

Yoon, Geoffrey UCSD 2006 MD


None None Cardiology Fellow Stanford 2011

Ellie Stadnick 2011-12 Clinical patient care; research

Mahazarin Ginwalla

2011-12 Clinical patient care; research

FACULTY

Pham, Michael UCSF 2000 MD

2005-current

Research Career development

Gene expression profiling for monitoring acute rejection

NEJ M. 2010 362(20) JHLT. 2010 29(3) JHLT. 2009 28(4) Am J Transpl. 2008 8(9) Am Heart J. 2008 155(5) JHLT. 2007 26(8) JHLT. 2006 25(12)

Clinical Asst. Professor Stanford University 2008-

Khush, Kiran Harvard 2000

2008 -current

Research Career

Clinical Trials

Expert Opin Emerg Drugs.

Asst. Professor




MD development Genomic approaches to monitoring acute rejection & CAD Sex/gender disparities in heart transplant

2009 Mar;14(1):1-21. PNAS. 2012 Cell. 2013 Science Translational Medicine: 2013 Under review

Stanford University 2011-

Biadi, Ombretta Univ. Pisa 1980 MD


Metabolic abnormalities and CAV

J Heart Lung Transplant. 2007 Apr;26(4):324-30.

Clinical Professor Cardio-thoracic University Pisa, Italy

Agbor-Enoh, Sean Yaounde, 2002 MD, Georgetown 2008 PhD

2014-present Clinical

Research Genome Transplant Dynamics

None Staff clinician National Heart, Lung & Blood Institute Bethesda, MD

CLINICAL RESEARCH Genome Transplant Dynamics Protocol (# 15-CC-0115) Director, NHLBI Laboratory of Transplantation Genomics Primary Objective:

• To validate the predictive accuracy and receiver operator curve characteristics of the percentage of circulating cell-free donor-derived DNA (%ccfdDNA) in a multicenter, prospective cohort study of heart-and lung-transplant patients, recruited through a consortium* of 5 transplant centers in the Washington, DC metropolitan area.

• Chair, *Genome Research Alliance for Transplantation (GRAfT) Mid-Atlantic Consortium Secondary Objectives:

• To compare %ccfdDNA characteristics in AMR (antibody-mediated rejection) and ACR (acute cellular rejection)

• To determine early immunologic changes associated with changes in %ccfdDNA Director of Post-Transplant Clinical Research Program Research program focused on: a) Developing novel non-invasive methods for rejection surveillance and diagnosis. Strategies include imaging using echocardiography and MRI (new program); and genomic approaches including gene expression profiling and shotgun sequencing to detect free donor DNA in recipient blood as a marker of rejection. These programs involve trans-disciplinary collaborations with investigators at Stanford and across the US. b) Mechanisms of transplant atherosclerosis with a focus on the role of cytomegalovirus infection - sponsored by NIH Program Project Grant; personnel consists of 1 senior research associate, 1 research associate, 2 postdoctoral fellows and undergraduate students


c) Principal investigator for clinical trials in heart-transplant patients NIH DIVERSITY-RELATED RESPONSIBILITIES Seventy-five percent of my time is spent on the following activities: Coordinate diversity programs across NIH Extramural:

• Evaluate existing programs – outcomes and tracking

• Diversity Program Consortium (BUILD/NRMN/CEC)

• Policy development for funding, review

• National strategy for sustainability Intramural:

• Cluster hires and targeted recruitments

• Stadtman, Lasker, and targeted searches

• Tools to identify candidates

• Implicit bias testing/intervention

• Future Research Leaders Conference

• Programming to fill career transition gaps

• Diversity Catalysts program PROFESSIONAL SOCIETIES AND ORGANIZATIONS MEMBERSHIPS – PAST AND CURRENT 1988 American Association for the Advancement of Science 1990 American College of Cardiology 1991 American Federation for Clinical Research 1990 American Heart Association 1988 American Society for Echocardiography 1990 American Society of Transplant Physicians 1986 Association of Black Cardiologists, Inc. 1987 International Society for Heart Transplantation 1987 International Society for Hypertension in Blacks 1998 American Heart Association: Western States Affiliate SERVICE TO PROFESSIONAL ORGANIZATIONS 1996-98 American College of Cardiology: Member, Council on Basic Science; Council on Clinical Cardiology;

Heart Failure and Transplantation Committee 1995-2000 American Society of Transplant Physicians Intrathoracic Organs Committee: 1995-97 Scientific Advisory Committee: 1995-96 Awards Committee: 1996-99 Public advocacy committee: 1998-2000 1990-1993 Association of Black Cardiologists, Inc.: Member Board of Directors 1996 International Society for Heart Transplantation: Program Committee 1995 UNOS Scientific Advisory Committee 1995 NIH: Data Safety Monitoring Board for REMATCH trial: 1998-2001


1998-2006 American Heart Association: Western States Affiliate: 1998-01 Member of Board of Directors 1999-02 Chairperson of Advocacy Committee 2002-03 President elect: 2004-06 President American Heart Association Western States Affiliate 2006-12 Castilleja School Board of Directors – member 2013-14 National Academy of Science Committee on Science of Team Science - Member SERVICE TO EDITORIAL BOARDS / REVIEWER 1998-13 Editorial Board, Graft 1998-13 Transplantation proceedings 1998-13 Editorial board, Ethnicity & Disease 2000-13 Journal Heart Lung Transplant 2000-13 Transplant Infectious Disease SERVICE COMMITMENTS – CURRENT NIH Advisory Board for Clinical Research - Member SERVICE COMMITMENTS – PRIOR 9/88-8/00 Medical Student Admission Committee 9/90-9/99 Medical School Committee on Diversity 9/97-8/00 Senator-at-Large, Medical School Faculty Senate, Stanford University 9/00-9/02 Stanford Committee for Development of a Women’s Health Curriculum 7/02-6/04 Medical School Appointments and Promotion Committee 1995- Women’s Health@Stanford- Board Member 3/06-10/06 Search Committee for Stanford University Vice-Provost of Research 3/06-10/06 Search Committee for Stanford University Vice-Provost of Graduate Education 9/2008-12/2013 Stanford University Diversity Cabinet – Advisory to Provost - Member 9/2008-12/2013 Stanford University Panel on Faculty Equity - Advisory to Provost – Member 9/2008-12/2013 Stanford University Women’s Forum - Member

RESEARCH AWARDS AND GRANTS

COMPLETED FEDERAL AND FOUNDATION SPONSORED RESEARCH 1DP4GM096849-01 – NIH Director Pathfinder Award PI: H. Valantine 9/30/2010 – 8/31/2013

Eradicating stereotype threat: intervening to retain and advance women faculty. Goal: To test the hypothesis reduction in stereotype threat (ST) to women would make a key difference to their ability to advance in the social and political structure of an academic environment. Role: Principle Investigator responsible for all aspects of a trans-disciplinary research project RC4 AI92673-01 PI (s): H. Valantine and S. Quake 9/30/2010 – 9/29/2013 Donor Genome Dynamics: Non-invasive, sequencing-based diagnoses of rejection. To monitor levels of donor genome in recipient blood as a noninvasive method for early detection of acute rejection in heart and lung transplant recipients. Role: Principle Investigator in a Multiple PI plan Sponsor: NIH


1UL1 RR025744-01 PI: H Greenberg; PD: H. Valantine 05/1/08 – 30/04/13 NIH. Stanford CTSA – Career Development and Diversity (CDD). The major goal of the CDD is to develop programs, policies, and a cultural home to support the career development of faculty and trainees engaged in clinical and translational research, and to enhance the gender and racial/ethnic diversity of the CTR community. Role: Program Director for Career Development and Diversity R01 HL093475 PI: Fearon; Co-Investigator: H. Valantine 06/1/09 - 05/31/14 ACE Inhibition and Cardiac Allograft Vasculopathy. To investigate the effect of ACE-inhibitors on the development of CAV in cardiac transplant recipients using a randomized, double blind, placebo-controlled study design. Role: Co-Investigator responsible for enrollment and heart transplant follow-up Sponsor: NIH

UO1-AI63623 PI: Mohamed Sayegh; Site PI H. Valantine 09/30/10 – 08/31/15 Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan®) Therapy In Cardiac Transplantation Clinical Trials in Organ Transplantation (CTOT-11) Role: PI for Stanford site for recruitment and patient follow-up Sponsor: NIH - NIAID

Protocol# 20442 PI: M. Phillips; Site PI: H. Valantine 09/1/10 - 08/31/13 NIH. Heartsbreath test for heart transplant rejection Role: PI for Stanford site for recruitment and patient follow-up Sub-contract with Menssana Research, Inc

1 PO1 A150153 PI: Mocarski; Co-PI H. Valantine 09/1/01 - 08/30/06 NIH, Transplant Arteriosclerosis: Viral and Host Mechanisms. Goal: to characterize viral and host responses during progression to transplant arteriosclerosis, and determine how these responses perturb the nitric oxide synthase pathway in the disease process. Role: Co- Principal Investigator and Core Project Leader.

U10 HL58706 Site PI: Valantine 06/1/99 - 05/31/05 Randomized trial of Azithromycin and Coronary Events Study (ACES). Goal: to determine if Chlamydia infection can be causally linked to cardiovascular events, using a clinical trial

approach. Sponsor: NIH

Grant-in-aid - American Heart Association - National PI: H. Valantine 1/1/96 -12/31/99 Mechanisms of Diabetes-Induced Transplant Atherosclerosis Goal: To determine the role of diabetes in a rodent model transplant atherosclerosis

Sponsor: AHA

R3HL63532A PI: H. Valantine 8/1/99 – 5/31/00 Optimization of rodent models of Transplant CAD Goal: To optimize a rat model of diabetes-induced transplant atherosclerosis Sponsor: NIH (SBIR) Grant-in-Aid - American Heart Association California Affiliate PI: H. Valantine 7/1/93 - 6/30/96 Mechanisms of Transplant Myopathy Goal: To study the role of cytokines in depression of cardiac function in the transplanted heart Sponsor: AHA – California Affiliate


OTL Research Incentive Fund Award PI: H. Valantine 7/1/92-6/30/93 Role of cytokine gene expression in cardiac dysfunction

Goal: To study the role of cytokines in acute rejection Sponsor: Office of Technology Licensing, Stanford University School of Medicine

HL02447-01: NIH Clinical Investigator Award – KO8 PI: H. Valantine 9/1/91-8/31/96 Immune Mediators of Allograft Dysfunction Goal: To identify the immune mechanisms mediating acute rejection and cardiac allograft dysfunction in heart transplant patients Sponsor: NIH

Biomedical Research Support Grant No. 2HLC532 PI: H. Valantine 7/3/88 - 6/30/89 Immune Mediators of Acute Allograft Function Goal: To identify the mechanisms medicating allograft dysfunction Sponsor: Stanford University

COMPLETED – INDUSTRY SPONSORED RESEARCH

09/1/05 – 03/31/10: A 24-month, Multi-center, Randomized, Open-label Non-inferiority Study of Efficacy and Safety Comparing Two Exposures of Concentration-controlled Certican with Reduced Neoral versus 3.0g MMF with Standard Dose Neo. Role: Principal Investigator Sponsor: Novartis Pharmaceuticals Corp.

01/1/05 - 01/30/10: Invasive Monitoring Attenuation through Gene Expression (IMAGE) Trial PI: H. Valantine

Role: Principal Investigator and Chair – Study Steering Committee Goal: Multi-center, randomize trial of peripheral blood leukocyte gene expression for monitoring acute cardiac allograft rejection.

Sponsor: Expression Diagnostics Inc.

7/1/00-6/30/02: “A Two-year Randomized, Multi-center, Double-blind Trial of the Efficacy and Safety of SDZ-RAD vs. Azathioprine as Part of a Triple Immunosuppressive Therapy Regimen in De Novo Heart Transplant Recipients. Role: Principal Investigator Sponsor: Novartis Pharmaceuticals Corp. 6/1/99-5/30/01: Randomized trial to compare the safety and efficacy of Daclizumab with OKT3 for induction therapy after heart transplantation Role: Principal Investigator Sponsor: Roche Pharmaceuticals Inc.

6/30/99-5/31/03: Principal Investigator for randomized trial of effect of switch to mycophenolate Mofetil and reduction of cyclosporine for amelioration of renal dysfunction after heart transplantation Role: Principal Investigator Sponsor: Roche Pharmaceuticals Inc. 6/30/99-5/31/03: Principal Investigator for randomized trial of effect of switch to Mycophenolate Mofetil and reduction of cyclosporine for amelioration of renal dysfunction after heart transplantation Role: Principal Investigator Sponsor: Roche Pharmaceuticals Inc.


3/1/95-3/30/98: A Multicenter, Randomized, Double-Blind Study of the Safety, Tolerability, and Vascular Effects of Neoral vs. Sandimmune in Heart Transplant Patients. Role: Principal Investigator Sponsor: Novartis Pharmaceuticals Corp. 4/30/96-5/31/00: Echocardiography Core Lab Director for evaluation of LV function in randomized trial of Neoral compared to Sandimmune Role: Core-Lab Director Sponsor: Novartis Pharmaceuticals Corp. 4/1/94-3/30/95: "An Open-Label, Randomized Study of Mycophenolate Mofetil for Treatment of Refractory Acute Cellular Allograft Rejection in Solid Role: Principal Investigator Sponsor: Roche Pharmaceuticals Inc. 3/1/94-2/28/95: A Randomized, Double-Blind Placebo-Controlled Dose Response Study to Assess Safety and Efficacy of Oral Rapamycin in the Treatment of Acute Grade 2 and Grade 3 Cardiac Allograft Rejection Role: Principal Investigator Sponsor: Wyeth Pharmaceuticals Inc. PATENTS # PCT/US10/55604. Filed on November 5, 2010. “Non-Invasive Diagnosis of Graft Rejection in Organ Transplant Patients”. Quake, Stephen R., Snyder, Thomas M. and Valantine, Hannah INVITED LECTURES AND VISITING PROFESSORSHIPS – CARDIAC TRANSPLANT RESEARCH-RELATED

3/16/89 How to Diagnose Rejection. 38th Annual Scientific Session, American College of Cardiology, Atlanta, GA.

2/21/90 Update on Immunosuppression in Transplantation. Continuing Education Program, Good Samaritan Hospital of Santa Clara Valley, San Jose, CA.

3/17/90 Cardiac Transplantation: Indications, Utilization and Outcome. 2nd Annual Scientific Session, Association of Black Cardiologists, New Orleans, LA.

3/19/90 How to Diagnose Acute Rejection. 39th Annual Scientific Sessions, American College of Cardiology, New Orleans, LA.

3/14/91 Non-Invasive Diagnosis of Acute Rejection. Plenary session, 40th Annual Scientific Sessions, American College of Cardiology, Anaheim, CA.

9/26/91 PRO: Heart Transplantation Should Not Be Offered to Patients Over 50. 60th Annual Symposium on Cardiovascular Disease, San Francisco, CA.

10/26/91 Intravascular Ultrasound Imaging in Cardiac Transplant Patients: The Stanford Experience. Transplant Coronary Artery Disease Symposium, St. Louis University Medical Center, St. Louis, MO.

5/18/92 Long-Term Results/Complications After Heart Transplantation: The Stanford Experience. Visiting Professor in Heart Transplantation, Thorax center, Erasmus University, Rotterdam, The Netherlands.

5/19/92 Monitoring Acute Rejection by Echocardiography. Visiting Professor in Heart Trans-plantation, University Hospitals of Rotterdam and Utrecht, The Netherlands.

8/7/92 Heart Transplantation. Health Matters television broadcast, KTEH-TV, Channel 54 (PBS), San Jose, CA.

10/26/92 Molecular Biology for the Cardiologist. The Learning Center, American College of Cardiology, Bethesda, MD

1/08/93 Heart Surgery Outcomes: Differences in Men and Women. Little Company of Mary Hospital, Los Angeles, CA.


5/17/93 Long-Term Management Issues of Atherosclerosis/Accelerated Coronary Artery Disease in Heart Transplant Recipients. 13th Annual Meeting, American Society of Transplant Physicians.

9/24/93 Transplant Coronary Arteriopathy: Understanding the Pathophysiology and Improving Strategies for Detection and Management. Society of Kananaskis, Alberta Cardiovascular Society, Alberta, Canada.

10/26/93 Target: 2000 -- Cardiovascular Medicine. Career Day, El Dorado Elementary School, San Francisco, CA.

11/5/93 Heart Attack: A Family Affair. Health Matters television broadcast, KTEH-TV, 11/6/93 Channel 54 (PBS), San Jose, CA. 11/8/93 Cardiac Transplantation: Expectations and Alternatives. Moderator, Postgraduate Seminar, 66th

Annual Scientific Sessions, American Heart Association, Atlanta, GA. 2/16/94 Cardiac Excitation, Rhythms, and Arrhythmias. Human Physiology Course, Stanford University

School of Medicine, Stanford, CA. 3/11/94 Transplantation: An Update. 6th Annual Scientific Sessions, Association of Black Cardiologists,

Atlanta, GA. 3/16/94 Treatment Options for End-Stage Heart Failure. 43rd Annual Scientific Session, American College

of Cardiology, Atlanta, GA. 3/17/94 Cardiac Transplantation. 43rd Annual Scientific Session, American College of Cardiology, Atlanta,

GA. 9/28/94 Complications of Cardiac Transplantation, Focusing on TxCAD. Visiting Professor, Ochsner

Cardiac Transplant Center, New Orleans, LA. 9/28/94 Mechanisms of Allograft Vascular Disease. Visiting Professor, Grand Rounds, Ochsner Cardiac

Transplant Center, New Orleans, LA. 1/31/95 Role of Lipids in Allograft Vascular Disease. 2d Symposium on Cardiac Allograft Vasculopathy, St.

Louis, MO. 2/11/95 Congestive Heart Failure: The Tired Heart. Health Matters television broadcast, 2/12/95 KTEH-TV, Channel 54 (PBS), San Jose, CA. 4/7/95 Correlation of Non-Immune Risk Factor with the Development of Transplant Coronary Artery

Disease. 15th Annual Scientific Session, International Society for Heart and Lung Transplantation, San Francisco, CA.

6/28/95 Cardiac Transplants. Internal Medicine Grand Rounds, Kaiser Permanente Medical Center, Oakland, CA.

8/9/95 Invited faculty for symposium, Immune Mechanisms of Cardiovascular Disease: 1) Role of cytokines in myocarditis; 2) Role of cytokines in acute rejection; 3) New immunosuppressive drugs. University of Colorado Health Sciences, Denver, CO.

9/18/95 Chairperson/Moderator: Is Echocardiography Useful for Monitoring Acute Rejection? International meeting, International Society for Heart and Lung Transplantation, Milan, Italy.

9/19/95 Is there a Relationship Between Acute Rejection(s) and Graft Coronary Artery Disease? International meeting, International Society for Heart and Lung Transplantation, Milan, Italy.

9/28/95 Long-Term Results of Heart Transplantation: Limitations Posed by Accelerated Allograft Vascular Disease. 3rd International Symposium on Advances in Cardiology and Cardiac Surgery, Rimini, Italy.

11/2/95 Keynote speaker, NHLBI Cardiovascular Minority Research Awardees Meeting. AHA 68th Scientific Sessions, Anaheim, CA.

1/16/96 Transplant Atherosclerosis: New Insights From Clinical and Pathologic Studies. Grand Rounds, College of Physicians and Surgeons, Columbia University, New York, NY.

2/26/96 Liver Pathology Conference. Stanford Liver Transplant Program, Stanford, CA. 3/14/96 Pathophysiology of Transplant Coronary Disease. XVIIe Séminaire de Cardiologie Pédiatrique,

“Artères Coronaires Chez L/Enfant,” Hôpital Necker, Paris, France. 3/16/96 CMV Prophylaxis With CMV Hyperimmune Globulin and Ganciclovir is More Effective Than

Ganciclovir Alone. Poster presentation, 16th Annual Scientific Session, International Society for Heart and Lung Transplantation, New York, NY.


3/17/96 Treatment of Recurrent/Refractory Rejection (co-chair). Breakfast symposium, 16th Annual Scientific Session, International Society for Heart and Lung Transplantation, New York, NY.

3/17/96 Impact of Prophylactic Immediate Post-Transplant Ganciclovir on Development of transplant Atherosclerosis: A Randomized Placebo-Controlled Study. Abstract presentation, 16th Annual Scientific Session, International Society for Heart and Lung Transplantation, New York, NY.

3/18/96 Strategies for Optimizing Immunosuppression After Heart Transplantation (co-chair). 16th Annual Scientific Session, International Society for Heart and Lung Transplantation, New York, NY.

3/26/96 Chronic Medical Management of the Heart Transplant Patient (Meet the Experts, co-chair). 45th Annual Scientific Session, American College of Cardiology, Orlando, FL.

4/11/96 Towards Healthier Hearts for Women. “Heart, Mind & Spirit: A Health Conference for Women.” American Heart Association, Michigan Affiliate, Ann Arbor, MI.

4/26/96 Current Strategies in Management of CMV Disease. Symposium by the University of Iowa Hospital, Division of Organ Transplantation. Tucson, AZ.

5/29/96 Cardiac Transplantation: Immunosuppression and Chronic Rejection (Concurrent Session 33, Chair). Annual Scientific Session, American Society of Transplant Physicians, Dallas, TX.

5/29/96 Metabolic Abnormalities Characteristic of Syndrome X Predict Long-Term Outcome in Heart Transplant Patients. (Abstract presentation). Annual Scientific Session, American Society of Transplant Physicians, Dallas, TX.

2/26/96 Liver Pathology Conference. Stanford Liver Transplant Program, Stanford, CA. 6/28/96 Long-Term Immunosuppression Management. Immunosuppression Symposium, Mycophenolate

Mofetil, Madrid, Spain. 6/28/96 Other Pharmacologic Adverse Effects: Prevention and Management. Immunosuppression

Symposium, Mycophenolate Mofetil, Madrid, Spain. 10/1/96 Vascular Complications of Diabetes: New Insights from Studies in Heart Transplant Patients and

Animal Models. American Heart Association Board Meeting, Millbrae, CA. 10/25-26/96 Chair: Symposium, “Individualizing Immunosuppression: Strategies for the Next Decade.”

Tucson, AZ. 10/26/96 Is TxCAD Primarily a Complication of a Metabolic Disorder? “Individualizing Immunosuppression:

Strategies for the Next Decade. Symposium, Tucson, AZ. 11/9/96 Transplant Arteriopathy Detection: Progression and Management. Cardiovascular Seminar #12,

69th Scientific Sessions, American Heart Association, New Orleans 11/22/96 Graft Vascular Disease: Prevention, Diagnosis, and Treatment. Current and Future Directions.

Immunosuppression Symposium, Roche Hospital, Madrid, Spain. 1/16/97 Transplant Atherosclerosis: Does Hypertriglyceridemia Play a Role? Stanford Clinical

Transplantation Forum, Stanford, CA. 1/30/97 The Role of CMV Disease in Transplant Atherosclerosis. Stanford CV Medicine Clinical

Conference, Stanford, CA. 3/28/97 Breakfast symposium, 17th Annual Scientific Sessions, International Society for Heart & Lung

Transplantation, London, UK. (coordinator and speaker (3/31); also served on Program Committee)

7/3/97 University of Michigan Medical Center: Role of CMV Disease in Transplant Atherosclerosis. July 1997.

9/17/97 University of Florida, Gainesville: CMV Disease after Cardiothoracic Transplantation. 10/2/97 Oregon Health Sciences University: The Role of CMV in Classical and Atherosclerosis and

Transplantation. 10/10/97 Sharp Memorial Hospital: Prevention of CMV Disease and Complications 10/10/97 University of California San Diego: CMV Disease and TXCAD: is there a link? 12/9/97 University of Kentucky: Role of CMV Disease in Transplant Atherosclerosis. 12/10/97 University of Cincinnati: 12/10/97: Role of CMV Disease in Transplant Atherosclerosis. 7/13/97 International Symposium on Current Problems in Heart Failure and in Cardiac Transplantation,

Thun, Switzerland. Randomized Trial of Efficacy of Mycophenolate Mofetil (MMF) Compared to Azathioprine for Prevention of Acute Rejection in Heart Transplant Patients.


7/13/97 International Symposium on Current Problems in Heart Failure and in Cardiac Transplantation, Thun, Switzerland. Targeting CMV and Metabolic Abnormalities to Prevent GVD.

3/1998 American College of Cardiology, symposium: Pathophysiology of transplant Coronary Artery Disease

4/10/98 Second Congress of the Spanish Society of Transplantation. Management of corticosteroid-resistant rejection.

4/10/98 Second Congress of the Spanish Society of Transplantation. Renal Failure after Heart Transplantation.

4/26/98 World Congress of Cardiology: Symposium: Congestive Heart Failure in African Americans. 5/17/98 17TH Annual Meeting of Association of Transplant Physicians, Symposium: Hyperlipidemia and

Cardiovascular Disease after Heart Transplantation. 5/18/98 17TH Annual Meeting of Association of Transplant Physicians, Plenary Session: Role of CMV

Disease in Chronic Rejection 5/10/98 Boston University, NIH-supported Symposium on Heart Failure: Issues Relevant to Gender and

Race: Predictors of outcome after Heart Transplantation. 7/15/98 International Society of Transplantation. Symposium: Prevention of Chronic Rejection. 7/16/98 International Society of Transplantation. Chairperson of Abstract Session: Prevention of Acute

Rejection. 8/1/98 Eleventh Annual Walter M. Booker Memorial Symposium: Treatment of Congestive Heart Failure in

African Americans. 9/28/98 Fourth Annual Astra Pharmaceuticals’ Cardiovascular Young Investigators forum. Faculty and

chairperson: Squaw Creek, California 10/12/98 Visiting Professor University of Queensland, Australia. Talks: 1. Role of echocardiography after heart transplantation 2. Pathophysiology of transplant coronary artery disease 3. Role of CMV disease in transplant coronary artery disease 10/19/98 European Thoracic Transplant Society Symposium: Assistance Hopitaux Publique de Paris: faculty

and speaker 1. RAD for prevention of Transplant Coronary artery disease in a rat model 2. Application of echocardiography for rejection surveillance 3. Results of the multicenter randomized trial of mycophenolate mofetil in heart transplantation.

10/22/98 Second Annual Symposium of the Transplantation Society of Vienna Role of CMVIG in prevention and treatment of CMV disease after heart transplantation 2/13/99 North Western Medical Society Annual Scientific Symposium: Sun valley: Faculty and Speaker: Is

hyperlipidemia important for heart disease in women? 3/6/99 American College of Cardiology Extramural Program: Cardiac transplantation: gender

considerations. 3/15/99 University of Colorado Health Sciences Center and UCLA Medical center Symposium: Thoracic

transplantation 1999: into the next millennium. Faculty and speaker 1. Evaluation of the heart transplant candidate with pulmonary 2. Coronary graft vasculopathy: immune and non-immune factors

3/18/99 Roche Transplantation Symposium: Monte Carlo. Faculty and speaker Long-term benefit of CMV prophylaxis after cardiac transplantation 4/6/99 Dinner symposium for transplant groups from Washington University, St. Louis University, and

Unity Medical Group. Role of CMV disease in long-term outcome after solid organ transplantation. 4/7/99 Visiting Professor Cardiac Transplant, St. Louis University, MO. New insights into transplant

coronary artery disease and chronic rejection. 4/7/99 Visiting Professor Cardiac Transplant, University of Missouri-Columbia. Role of CMVIG in outcome

after cardiothoracic organ transplantation. 5/16/99 American Society of Transplantation 18TH Annual Scientific meeting: Chairperson: Intrathoracic

Session: Immunosuppression after heart and lung transplantation


5/16/99 Round-Table symposium: Cytomegalovirus Infection in Transplant Patients: Current Issues and Future Directions: Impact of CMV in heart transplantation, specifically coronary artery vasculopathy.

6/10/99 European Society of Cardiology and the working group of the Thoracic Organ Transplantation of the German Society of Cardiology symposium: Changing concepts of the coronary circulation – perspectives beyond the usual. Faculty and speaker: 1. Chairperson & Moderator for Prevention and treatment of cardiac allograft vasculopathy 2. Talk: Statins et al for Prevention and treatment of cardiac allograft vasculopathy 3. Talk: Three-year results of the multicenter randomized trial of mycophenolate mofetil in heart transplantation

9/30/99 Fifth Annual Astra Pharmaceuticals’ Cardiovascular Young Investigators forum. Faculty and chairperson, Banff, Alberta, Canada

12/10/99 Tenth International Dresden Symposium on Lipoproteins and Atherosclerosis. Faculty and Speaker: Role of metabolic syndrome in allograft coronary disease

6/6/00 Nova Scotia meeting on Cytomegalovirus Talk: Role of CMV in complications after heart transplantation 11/2/00 Symposium on risk factors for coronary artery disease Talk: Role of diabetes as a risk factor for allograft vascular disease 11/9/00 International symposium on herpes virus infections: 8th annual meeting of the IHMF Talk: Role CMV in allograft vasculopathy: Indirect Effects 3/9/01 International symposium of transplant allograft disease Talk: Role CMV in allograft vasculopathy: Indirect Effects 3/3/01 Scientific Sessions of the Association of Black Cardiologists (ABC) Talk: Diastolic heart Failure 4/24/01 Visiting Professor at University of McGill, Montreal Talk: Immunosuppression in Heart transplant patients 4/12/01 International Society of Heart and Lung Transplantation Talk: Role of diabetes in allograft vasculopathy 4/29/02 Scientific Sessions American Society of Transplantation Talk: Pathophysiology of allograft vasculopathy 8/25/02 Congress of the Transplantation society- Miami Florida 1) Symposium Talk: Proliferation Signal Inhibitors for Prevention of Allograft Vascular Disease 2) Presentation of results in Everolimus trial 9/25/02 Symposium of the Nordic Society of Transplantation. Talk: Role of CMV in the Pathophysiology of allograft vascular disease 10/17/02 Novartis Advisory group for the use of proliferation signal inhibitor in heart transplantation:

Stockholm Sweden Talk: Proliferation Signal Inhibitors for Prevention of Allograft Vascular Disease: results of the

Everolimus trial 11/6/02 Lectures to the multi-organ transplant programs at University of Toronto and Montreal 1) Mechanisms of allograft vascular disease 2) Role of Tacrolimus in prevention of cardiac allograft dysfunction 11/12/02 Novartis Advisory group for the use of proliferation signal inhibitor in heart transplantation:

Cambridge- United Kingdom Talk: Proliferation Signal Inhibitors for Prevention of Allograft Vascular Disease: results of the

Everolimus trial 11/13/02 International Symposium on organ transplantation: Roche- Monte Carlo Talk: Role of CMV infection in Allograft Vascular Disease: Indirect effects of the virus 12/2/02 Visiting Professor and Thesis Examiner- University of Rotterdam Talk: Pathophysiology of Allograft vascular Disease: New directions 4/9/03 International Society of Heart and Lung Transplantation Annual Scientific Sessions: Luncheon

symposium on CMV


Evidence for CMV involvement in the pathophysiology of allograft vascular disease 6/27/03 Novartis Advisory group for the use of proliferation signal inhibitor in heart transplantation: Palma

Majorca, Spain Talk: Proliferation Signal Inhibitors for Prevention of Allograft Vascular Disease: results of the

Everolimus trial 12/14/03 Working group on Post Transplant diabetes in solid organ transplants Talk: Role of diabetes in allograft vasculopathy 12/18/03 Visiting Professor and thesis examiner for the University of Helsinki, Finland Talk: Pathophysiology of allograft vasculopathy: Role of CMV infection 4/10/04 International Society of Heart and Lung Transplantation, Japan Speaker: Pathophysiology of Allograft Vascular Disease 5/08/04 American Society of Transplantation: Chicago Chair Scientific session on heart transplantation 7/1/04 University Munich Heart Transplant Symposium. Metabolic factors in cardiac allograft

Vasculopathy 9/7/04 Master-class Symposium: Chair Person. Vienna Talk: Role of proliferation signal inhibitors in heart transplantation. Transition from clinical trial to

clinical practice. 11/2/04 Improving Life Trough Innovation: A Transplant Symposium: University of Toronto Talk: Pathophysiology of allograft vasculopathy; new evidence for CMV disease in the

pathophysiology 4/6-9/05 International Society of Heart and Lung Transplantation Annual Scientific Meeting Philadelphia -

2005. Prevention of Cardiac allograft vasculopathy in Clinical practice 4/6-9/05 International Society of Heart and Lung Transplantation Annual Scientific Meeting Philadelphia -

2005. New look at old hat – Moderator oral poster session 5/21/05 American Society of Transplantation - 24th Annual Meeting, May 20-25, Seattle: Symposium on

medical complications of organ transplantation - Chairperson 9/30/05 Transplant coordinators conference - Las Vegas. Diagnosis and treatment of Cardiac Allograft

Vasculopathy 10/16/05 Master-class Symposium Geneva - Chair Person Talk: Role of proliferation signal inhibitors in heart transplantation – Impact on Cardiac allograft

vasculopathy and renal function 4/5/06 Master-class Symposium - Madrid: Chair Person Talk: Role of proliferation signal inhibitors in heart transplantation – Impact on malignancy 4/3-8/06 International Society of Heart and Lung Transplant Annual Scientific meeting: Symposium on Viral

infections after heart and lung transplantation: Prophylactic Strategies for CMV and EBV 2/19-23/07 Masters-to-Masters International Workshop on Proliferation Signal Inhibitors (PSI) in Heart

Transplantation - Barcelona Spain – Chair and speaker. 2/15/07 Canadian Society of Transplantation Annual Scientific meeting: Cardiac Allograft Vasculopathy and

Cytomegalovirus. 4/10/07 International Society of heart and Lung transplantation Annual Scientific Meeting – San Francisco:

Symposium on non-invasive diagnosis of acute rejection: Role of Echocardiography and MRI 4/13/08 University Pisa, Italy - Visiting professor: Pathophysiology of cardiac Allograft Vasculopathy 4/16/07 University Bologna, Italy - Visiting professor: Cardiac Allograft Vasculopathy - An Overview -

Accelerating Towards the Solution 4/17/07 Italian society of heart Transplantation Symposium – Naples Italy: Cardiac Allograft Vasculopathy -

An Overview 5/09/07 American Society of Transplantation Annual Scientific Meeting – San Francisco: Cardiac Allograft

Vasculopathy Any Progress? 6/26/07 University of Manchester Heart Transplant Center: Prevention of cardiac Allograft vasculopathy –

inhibition of CMV activation.


6/27/07 Papworth Hospital, Cambridge University: Role of Cytomegalovirus infection in transplant allograft vasculopathy – prevention with longterm antiviral inhibition.

6/28/07 Harefield Hospital Heart Transplant Center: Prophylactic Strategies for CMV - is there a case for life-long prophylaxis?

6/28/07 Freeman Hospital Heart Transplant Center – Newcastle University: Prophylactic Strategies for CMV - is there a case for life-long prophylaxis?

6/29/07 Glasgow Royal Infirmary Cardiothoracic Transplant Unit: Role of Cytomegalovirus infection in transplant allograft vasculopathy – prevention with long-term antiviral Drugs.

4/8/08 International society of heart and lung transplantation annual scientific meeting: symposium on Cardiac Allograft Vasculopathy. Role of non-immune factors in the pathophysiology of CAV.

6/22-26/09 Visiting Professor University Calgary and Toronto Multi-organ Transplant Programs CMV impact solid organ transplantation: new insights on subclinical infection & metabolic

interactions Metabolic abnormalities and their effects on outcomes after heart transplant: systemic inflammation

and infection 10/1/09 Johns Hopkins Department of Medicine Visiting Professor – Research Conference: Gene Expression Profiling for Diagnosis of Acute Rejection after Heart Transplantation 10/2/09 Johns Hopkins Department of Medicine Visiting Professor – Grand rounds: Cardiac allograft vasculopathy: Old Problem – New Insights: Obesity, Viruses and Inflammation 1/13-14/2010 Saint Luke’s Mid-America Heart Institute 4/20/10 Chair, ISHLT – Satellite Symposium: Cardiac Allograft Vasculopathy: From Bench to Bedside

(Waldorf). Chicago, IL 2/4/11 Cardiac allograft vasculopathy: Old Problem – New Insights: Obesity, Viruses and Inflammation Genomic approaches to diagnosis of heart transplant rejection: Club de la Transplantation 2011 –

Paris 3/3/11 Genomic approaches to diagnosis of heart transplant rejection: Peripheral Blood Leukocyte Gene

Expression and Circulating Cell-free Donor DNA. The Future of Genomic medicine IV - Scripps Institute for Translational Medicine; San Diego, CA

4/13/11 Transplant Vasculopathy: An Overview. ISHLT 31st Annual Meeting. San Diego, CA 9/20/11 The Promise of Personalized Medicine - Genomic Approaches for Monitoring Rejection after Heart

Transplantation. LKSC – Berg Hall. 10/19/11 Advances in Heart Transplantation. LKSC-MED 223 / Cardiovascular and Pulmonary Sciences

Seminar. 2/24/12 CMV in Thoracic Transplantation. Symposium: Effect of Chronic Viral Infection on Outcomes in

Solid Organ Transplantation. LKSC-Berg Hall. 3/14/13 C1q and post-transplant outcomes. Canadian Cardiac Transplant Network. Lake Louise, Alberta. 3/16/13 Clinical Use of Cardiac Transplant Biomarkers in Rejection Monitoring. Canadian Society of

Transplantation. Lake Louise, Alberta. 4/25/13 Debate protagonist: Heart Biopsy is not necessary for routing monitoring of patients after heart

transplantation: ISHLT 33rd Annual Meeting and Scientific Sessions. 4/25/13 ISHLT 33rd Annual Meeting and Scientific Sessions. Co-chair, Concurrent Session 14: Living with

a Transplanted Heart: A Narrow Pathway in the Jungle. Montreal, Canada 7/1/13 Moderator – education and training for team science. National Academy of Science – Science of

Team Science Workshop 8/20/13 Making culture changes that respect and enhance workforce diversity. Stanford Human Resources

Group Annual Conference 8/21/13 Workplace innovations: changing the culture of academic medicine to support diversity, excellence

and faculty in the 21st Century. UCSF Department of neurology 11/10/13 Can institution-wide interventions ameliorate unconscious bias: evidence beyond observational

studies? Society for Neuroscience; San Diego, CA 4/21/15 Precision Medicine in Action: Applying Genomic Tools to Improve Patient Outcomes After Organ

Transplantation. 2015 Anita B. Roberts Lecture Series: Distinguished Women Scientists at NIH


1/7/16 Precision Medicine in Action: Applying Genomic Tools to Improve Transplant Health Outcomes. National Human Genome Research Institute Division of Intramural Research Genome Seminar Series

1/15/16 Precision Medicine in Action: Applying Genomic Tools to Improve Transplant Health Outcomes. LeNoire Hamburger Lecture, University of California, San Diego

11/9/16 Precision Medicine in Action: Applying Genomic Tools to Improve Transplant Health Outcomes. FDA CDER Seminar Series

03/17/17 Beyond Biopsy: Using Genomics to Quantify Transplant Outcomes. Cardiovascular Frontiers Forum, Stanford University

05/15/17 Precision Medicine in Action: Applying Genomic Tools to Improve Transplant Health Outcomes. Medical Grand Rounds, Feinberg School of Medicine, Northwestern University

07/19/17 Precision Medicine in Action: Applying Genomic Tools to Improve Transplant Health Outcomes. Medical Grand Rounds, Cleveland Clinic

INVITED LECTURES – HEART DISEASE IN WOMEN 1/08/93 Heart Surgery Outcomes: Differences in Men and Women. Little Company of Mary Hospital, Los

Angeles, CA. 11/5/93 Heart Attack: A Family Affair. Health Matters television broadcast, KTEH-TV, & 11/6/93 Channel 54 (PBS), San Jose, CA. 11/4/94 Toward Healthier Hearts for Women. McGann Women and Health Series, Stanford University

School of Medicine, Stanford, CA. 4/22/95 The Vascular Wall Effects of Hormone Replacement and Their Impact on Cardiovascular Disease.

Stanford University School of Medicine, Stanford, CA. 5/19/95 Cardiovascular Disease in Women: Difficulties in Diagnosis and Treatment. American Heart

Association (Michigan chapter), Lathrup Village, MI. 1/6/96 Women and Healthy Hearts Health Matters television broadcast, KRON-TV, Channel 4 (NBC),

San Francisco, CA. (M-F, 1:30 & 5:00 am, Tu-F, 9:30 am) 4/11/96 Towards Healthier Hearts for Women. “Heart, Mind & Spirit: A Health Conference for Women.”

American Heart Association, Michigan Affiliate, Ann Arbor, MI. 1/20/97 Women and Heart Disease Television broadcast, Cable Co-op Channel 6, San Francisco, CA. (Th

5:30 pm; Sat 6:30 pm) 2/13/99 North Western Medical Society Annual Scientific Symposium: Sun valley: Faculty and Speaker: Is

hyperlipidemia important for heart disease in women? 3/6/99 American College of Cardiology Extramural Program: Cardiac transplantation: gender

considerations. 5/11/02 Symposium of Midlife Women’s’ Wellness Talk: Women and Heart Disease 5/10/03 Women’s Wellness Symposium presented by Women’s Health@Stanford Update on Heart Disease in Women 5/9/04 American Heart Association Women’s Luncheon- Spanish Bay, California Update on Heart Disease in Women 9/23/04 AHA Young Investigators Awards: Key Note Speaker Heart Disease in Women: Building awareness 12/11/04 Stanford Symposium on Women’s Health: Heart Disease in Women of Color: Challenges in

Diagnosis and Management 4/29/05 American heart Association – Utah Board: Update on heart disease in women 5/14/05 Stanford Sierra Camp Educational Program: heart disease in women – challenges in diagnosis and

treatment


2/7/08 The Influence of Sex/Gender on Cardiovascular Health. Littlefield Women's Health Public Forum; Stanford University:

2/12/13 Heart Disease in Women. Northwestern Medical Dental Association. Sun Valley, Idaho

INVITED LECTURES – DIVERSITY, LEADERSHIP AND CAREER DEVELOPMENT 11/2/95 Keynote speaker, NHLBI Cardiovascular Minority Research Awardees Meeting. AHA 68th

Scientific Sessions, Anaheim, CA. 7/21/06 Stanford Medical Youth Science Program (SMYSP): Opportunities as healthcare professionals – a

new perspective. 7/27/06 The Stanford Summer Research Program (SSRP) in Biomedical Sciences: Careers in academic

medicine – a personal perspective 9/18/06 Women's Global Health Scholars Program – UCSF: Achieving Diversity through Leadership:

Challenges and Practical Solutions for Career Advancement of People Underrepresented in Science and Medicine

12/16-19/06 AAMC Mid-Career Women Faculty Career Development: Meeting Management and Making your Voice Heard

2/16/07 Canadian Transplant Academy Training Day: “Faculty Satisfaction: Today’s Challenges, Tomorrow’s Hope for Survival of the Academy”

8/2/07 Stanford Summer Research Program "Women and Minorities in Science" seminar. Pathways to career success.

10/27/07 First annual SUMC Summit for Clinical Excellence: Diversity and Excellence 11/27/07 NIH National Leadership Workshop on Mentoring Women in Biomedical Careers Chair Workshop: Determining gaps in Mentoring Programs and Developing Novel models for

Successful Mentoring 4/1/08 Stanford University Biosciences Brunch. Commitment to Diversity and Career Advancement

Opportunities at Stanford. 4/4/08 Tufts University Women in Science Symposium. Faculty Diversity: Strategies for Hiring & Retaining

a Diverse Workforce 4/26/08 Stanford University School of Medicine Admit Week: Women in Medicine – Diversity and career

Advancement Opportunities at Stanford. 5/20/08 "Careers in Medicine" series for medical students and undergraduates: A personal perspective on

innovation, leadership and excellence 6/2-6/08 Stanford Center for Clinical and Translational Science – Intensive course on clinical research for

graduate medical education trainees: Mentor 6/18/08 Stanford School of Medicine Faculty Senate: Update on Leadership and Diversity at the School of

Medicine: are we making progress? 7/3/08 Stanford Students Early Matriculation Program: Leadership in academic medicine - combining

innovation with clinical care; a personal perspective. 10/9/08 Stanford Women and Medicine Student Association: Talk: "From West Africa to heart

transplantation: A personal reflection -on pathways to Career advancement for women in academic medicine"

10/14/08 Grand Rounds - Division of Plastic Surgery – Stanford. Strategies for expanding faculty and trainee diversity in medicine.

11/6/08 Stanford Medical Student leadership Development Course: Leadership as the Lever for Diversity. 10/1/09 Johns Hopkins department of Medicine Visiting Professor Developing women and minorities in medicine 12/8/09 Robert Wood Johnson Foundation Physician Scholars Program National Advisory Committee: Mentoring Models & Leadership Development at Stanford School of Medicine: Application to RWJF

Physician Faculty Program


Robert Wood Johnson Foundation Physician Scholars Program Local Mentors: Current Best Practices in Mentoring: The Stanford Approach 3/24/10 Robert Wood Johnson Foundation Physician Scholars Program Webinar Series Mentoring Models & Leadership Development Principles & Best Practices 4/27/10 Diversity, Cultural Competencies, Hiring, and Retaining a Diverse Workforce. Women in Science

and Medicine Symposium. Anaheim, CA 10/26/10 Women in World Neuroscience International Brain Research Organization - University British

Columbia Institute of Neuorethics, Canada Women in the Pipeline of Neuroscience - Careers Developing Women as Leaders 12/8/10 Robert Wood Johnson Foundation Physician Scholars Program National Advisory Committee: Mentoring and Leadership Development in the Robert Wood Johnson Foundation Physician

Scholars Program: Early outcomes of a new pilot program 3/10/11 Women and Inclusion in Academic Medicine. Presentation of member ARRA Grants. Harvard

Medical School. Boston, Ma 4/5/11 Career Panelist / Career Advancement of Women. 5/2/11 National Advisory Committee – School of Medicine. Progress-Developing Flexible Careers 5/19/11 Stanford University Faculty Women's Forum/Leadership@Stanford – Discussant 11/29/11 2011 National Meeting / The Robert Wood Johnson Foundation Physician Faculty Scholars

Program. Update on mentoring program. San Diego, CA. 2/7/12 Leadership and Diversity. Ruth Jackson Orthopaedic Society (RJOS) Leadership Conference.

San Francisco, CA 3/29/12 Leadership & Diversity: Changing Face of Women in Medicine. Group in Women and Medicine in

Science (GWIMS). University of California, Davis 4/23/12 Progress and Challenges in Enhancing Diversity and Leadership. National Advisory Committee –

School of Medicine. 5/22/12 Leadership & Diversity: Changing Face of Women in Academic Medicine. Surgical Grand Rounds.

University of San Diego, CA 6/14/12 Context and Case for Faculty Career Flexibility in Academic Medicine. Work and Family

Researchers Network. New York City, NY 1/11/13 Science of Team Science/The National Academy of Sciences. Panel Discussion: Emerging

Challenges of Team Science. Washington, DC 1/25/13 Challenges and Opportunities for Women in Leadership. XX in Health Retreat. San Francisco, CA 3/5/13 Academic Biomedical Career Customization. American Council on Education Annual Meeting.

Washington, DC 5/15/15 Scientific Workforce Diversity: Opportunity for Enhancing Research Excellence. Understanding

Interventions for Broadening Participation in Science Careers, San Diego, CA 5/8/15 Faculty Career Flexibility – National Imperative. ATVB Women's Leadership Luncheon, American

Heart Association 6/24/15 Managing Life and Career: Integration Instead of Balance? Children’s National Hospital Grand

Rounds, Washington, DC 8/1/15 Diversity in Research and Academia: NIH Perspective. National Medical Association 113th Annual

Convention and Scientific Assembly, Detroit, MI 8/26/15 Enhancing Diversity in the Scientific Workforce: An Opportunity and Imperative for Excellence.

HHS Office of Women’s Health Women’s Equality Day, Washington, DC 9/18/15 Enhancing Effectiveness in Diverse Teams: Leadership Approaches. National Academies

Symposium on Enhancing the Effectiveness of Team Science, Washington, DC 9/20/15 Diversity as a Driver of Institutional Excellence. AAMC Minority Faculty Development, Washington,

DC 10/23/15 Eliminating the Gender Leadership Gap in Academic Medicine: 50/50 by 2020. Successful

Strategies for Women in Academic Medicine, University of Pennsylvania, Philadelphia 11/11/15 Enhancing Diversity in the Scientific Workforce: An Opportunity and Imperative for Excellence

(keynote). Annual Biomedical Research Conference for Minority Students. Seattle, WA


3/8/16 Enhancing Scientific Workforce Diversity: Imperative for Institutional Excellence. HHMI Janelia Research Campus 3/28/16 Enhancing Scientific Workforce Diversity: Imperative for Institutional Excellence. Howard, Dorsey,

Still Lecture, Harvard University 5/6/16 Enhancing Scientific Workforce Diversity: Imperative for Institutional Excellence. UC-Wide Health

Sciences Leadership Development Conference: Paths to Leadership and Inclusion Excellence 6/3/16 Planning for Success: The Importance of Mentoring and Networking in Biomedical Research.

FASEB Postdoctoral Preparation Institute 6/9/16 NIH AA/B Funding Disparity Working Group: Findings and Recommendations. NIH ACD Meeting 9/21/16 NIH Addresses the Science of Diversity: Where Are We Now? Dean's Lecture Series: Fresh

Perspectives on Diversity. (Stanford University School of Medicine) 9/27/16 Understanding Diversity Through a Scientific Lens. Excellence in Diversity Symposium: Invent and

Represent. (Johns Hopkins University) 10/13/16 Understanding Diversity Through a Scientific Lens. SACNAS Annual Meeting Keynote 11/14/16 NIH Addresses the Science of Diversity: Where Are We Now? Xavier University 3/6/17 Precision Medicine in Action: Applying Genomic Tools to Improve Health Outcomes. Icahn School

of Medicine at Mount Sinai 3/27/17 NIH Addresses the Science of Diversity. AAAS Fellowship Symposium, Washington, DC 4/28/17 NIH Addresses the Science of Diversity: Where Are We Now? Advancing Gender and Under-

Represented Minority (URM) Equity in Biomedical Careers, AAMC, Washington, DC 05/15/17 NIH Addresses the Science of Diversity: Focusing on Institutional Change Feinberg School of

Medicine, Northwestern University 7/19/17 NIH Addresses the Science of Diversity: Focusing on Institutional Change, Cleveland Clinic 7/17/17 NIH Addresses the Science of Diversity: Institutional Change as the Path to Sustainability,

Preparing the Next Generation of Neuroscience Leaders, Society for Neuroscience (Washington, DC)

7/27/17 Enhancing Scientific Workforce Diversity: Imperative for Institutional Excellence, Association of Pathology Chairs Diversity and Inclusion Lecture, Washington, DC

PUBLICATIONS M.D. Thesis (London University, 1988) Doppler echocardiographic assessment of left ventricular function in cardiac allografts and its application for rejection surveillance. JOURNAL ARTICLES Original Research (Most recent first) 153. Sharon E, Shi H, Kharbanda S, Koh W, Martin LR, Khush KK, Valantine H, Pritchard JK, De Vlaminck I.

Quantification of transplant-derived circulating cell-free DNA in absence of a donor genotype. PLoS Comput Biol. 2017 Aug 3;13(8):e1005629.

152. Parikh RV, Khush KK, Luikart H, Pargaonkar VS, Kobayashi Y, Lee JH, Sinha S, Cohen G, Valantine HA, Yeung AC, Fearon WF. Impact of Asymmetric Dimethylarginine on Coronary Physiology Early After Heart Transplantation. Am J Cardiol. 2017 Jun 29. pii: S0002-9149(17)31044-5.

151. Agbor-Enoh S, Tunc I, De Vlaminck I, Fideli U, Davis A, Cuttin K, Bhatti K, Marishta A, Solomon MA, Jackson A, Graninger G, Harper B, Luikart H, Wylie J, Wang X, Berry G, Marboe C, Khush K, Zhu J, Valantine H. Applying rigor and reproducibility standards to assay donor-derived cell-free DNA as a non-invasive method for detection of acute rejection and graft injury after heart transplantation. J Heart Lung Transplant. 2017 May 20. pii: S1053-2498(17)31807-7.

150. Fearon WF, Okada K, Kobashigawa JA, Kobayashi Y, Luikart H, Sana S, Daun T, Chmura SA, Sinha S,


Cohen G, Honda Y, Pham M, Lewis DB, Bernstein D, Yeung AC, Valantine HA, Khush K. Angiotensin-Converting Enzyme Inhibition Early After Heart Transplantation. J Am Coll Cardiol. 2017 Jun;69(23):2832-2841.

149. Fearon WF, Felix R, Hirohata A, Sakurai R, Jose PO, Yamasaki M, Nakamura M, Fitzgerald PJ, Valantine HA, Yock PG, Yeung AC. The effect of negative remodeling on fractional flow reserve after cardiac transplantation. Int J Cardiol. 2017; 241:283-287.

148. Lee JH, Okada K, Khush K, Kobayashi Y, Sinha S, Luikart H, Valantine H, Yeung AC, Honda Y, Fearon WF. Coronary Endothelial Dysfunction and the Index of Microcirculatory Resistance as a Marker of Subsequent Development of Cardiac Allograft Vasculopathy. Circulation. 2017;135(11):1093-1095.

147. Okada K, Fearon WF, Luikart H, Kitahara H, Otagiri K, Tanaka S, Kimura T, Yock PG, Fitzgerald PJ, Yeung AC, Valantine HA, Khush KK, Honda Y. Attenuated-Signal Plaque Progression Predicts Long-Term Mortality After Heart Transplantation. JACC 2016 ;68(4):382-92.

146. Burnham P, Kim MS, Agbor-Enoh S, Luikart H, Valantine HA, Khush KK, De Vlaminck I. Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma.

Sci Rep. 2016 Jun 14;6:27859. 145. Yang HM, Khush K, Luikart H, Okada K, Lim HS, Kobayashi Y, Honda Y, Yeung AC, Valantine H, Fearon

WF. Invasive Assessment of Coronary Physiology Predicts Late Mortality After Heart Transplantation. Circulation. 2016 May 17;133(20):1945-50. 144. Reducing Implicit Gender Leadership Bias in Academic Medicine with an Educational Intervention. Girod S, Fassiotto M, Grewal D, Ku MC, Sriram N, Nosek BA, Valantine H. Acad Med. 2016 Jan 27. [Epub

ahead of print] 143. Paradoxical Vessel Remodeling of the Proximal Segment of the Left Anterior Descending Artery Predicts

Long-Term Mortality After Heart Transplantation. Okada K, Kitahara H, Yang HM, Tanaka S, Kobayashi Y, Kimura T, Luikart H, Yock PG, Yeung AC, Valantine HA, Fitzgerald PJ, Khush KK, Honda Y, Fearon WF. JACC Heart Fail. 2015 Dec;3(12):942-52.

142. Women in Academic Medicine: Measuring Stereotype Threat Among Junior Faculty. Fassiotto M, Hamel EO, Ku M, Correll S, Grewal D, Lavori P, Periyakoil VJ, Reiss A, Sandborg C, Walton G, Winkleby M, Valantine H. J Womens Health (Larchmt). 2016 Mar;25(3):292-8.

141. Monitoring pharmacologically induced immunosuppression by immune repertoire sequencing to detect acute allograft rejection in heart transplant patients: a proof-of-concept diagnostic accuracy study. Vollmers C, De Vlaminck I, Valantine HA, Penland L, Luikart H, Strehl C, Cohen G, Khush KK, Quake SR. PLoS Med. 2015 Oct 14;12(10):e1001890.

140. Noninvasive monitoring of infection and rejection after lung transplantation. De Vlaminck I, Martin L, Kertesz M, Patel K, Kowarsky M, Strehl C, Cohen G, Luikart H, Neff NF, Okamoto J, Nicolls MR, Cornfield D, Weill D, Valantine H, Khush KK, Quake SR. Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13336-41.

139. Gene expression profiling to study racial differences after heart transplantation. Khush KK, Pham MX, Teuteberg JJ, Kfoury AG, Deng MC, Kao A, Anderson AS, Cotts WG, Ewald GA, Baran DA, Hiller D, Yee J, Valantine HA. J Heart Lung Transplant. 2015 Jul;34(7):970-7.

138. Circulating Cell-Free DNA Enables a Non-Invasive Diagnostic for Heart Transplant Rejection. Iwijn De Vlaminck, Hannah A. Valantine, Thomas M. Snyder, Calvin Strehl, Garrett Cohen, Norma F. Neff, Jennifer Okamoto, Daniel Bernstein, "Dana.Weisshaar , Kiran K. Khush and Stephen R. Quake. Science Translational Medicine: 2014 June 18;6(241):241ra77

137. The Gender Gap in Academic Medicine: Comparing results from a Multifaceted Intervention for Stanford Faculty to Peer and National Cohorts. Hannah A. Valantine, MD; Daisy Grewal, PhD; Manwai Candy Ku, PhD; Julie Moseley, PhD; Mei-Chiung Shih, PhD; David Stevenson, MD; Philip Pizzo, MD. Acad. Med. 2014 June;88(6):904-11.

136. Utility of gene expression profiling score variability to predict clinical events in heart transplant recipients. Deng MC, Elashoff B, Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Cappola TP, Kao A, Anderson AS, Cotts WG, Ewald GA, Baran DA, Bogaev RC, Shahzad K, Hiller D, Yee J, Valantine HA; IMAGE Study Group. Transplantation. 2014 Mar 27;97(6):708-14.

http://www.ncbi.nlm.nih.gov/pubmed/24637869


135. Temporal Response of the Human Virome to Immunosuppression and Antiviral Therapy. Iwijn De Vlaminck, Kiran K. Khush, Calvin Strehl, Bitika Kohli, Norma F. Neff, Jennifer Okamoto, Thomas M. Snyder, David Weill, Daniel Bernstein, Hannah A. Valantine, and Stephen R. Quake. Cell 155.5 (2013): 1178-1187.

134. Identification of common blood gene signatures for the diagnosis of renal and cardiac acute allograft rejection. Li L, Khush K, Hsieh SC, Ying L, Luikart H, Sigdel T, Roedder S, Yang A, Valantine H, Sarwal MM. PLoS One. 2013 Dec 16;8(12)

133. Changing the Culture of Academic Medicine to Eliminate the Gender Leadership Gap: 50/50 by 2020. Hannah Valantine and Christy Sandborg. Acad. Med. 2013;88;No.10

132. Stevenson DK, Shaw GM, Wise PH, Norton ME, Druzin ML, Valantine HA, McFarland DA; on behalf of the March of Dimes Prematurity Research Center at Stanford University School of Medicine. Transdisciplinary translational science and the case of preterm birth. J Perinatol. 2012 Oct 18.

131. Snyder T, Khush K, Valantine H, and Quake S. Universal Noninvasive Detection of Solid Organ Transplant Rejection. PNAS, March 28, 2011.

130. Cécile T.J. Holweg, Luciano Potena, Helen Luikart, Tianwei Yu, Gerald J. Berry, John P. Cooke, Hannah A. Valantine and Edward S. Mocarski. Identification and Classification of Acute Cardiac Rejection by Intragraft Transcriptional Profiling. Circulation 2011, 123:2236-2243

129. Decisions, Decisions: How Program Diversity Influences Surgical Residency Program Selection. Ku MC, Li YE, Prober C, Valantine HA, Girod SC. J Am Coll Surg. 2011 Aug;213(2):294-305

128. Girod S, Gilmartin SK, PhD, Valantine H, Schiebinger L. Academic Couples: Implications for Medical School Faculty Recruitment and Retention. J Am Coll Surg. 2011 Mar;212(3):310-9

127. Chen R, Sigdel TK, Li L, Kambham N, Dudley JT, Hsieh SC, Klassen RB, Chen A, Caohuu T, Morgan AA, Valantine HA, Khush KK, Sarwal MM, Butte AJ. Differentially expressed RNA from public microarray data identifies serum protein biomarkers for cross-organ transplant rejection and other conditions. PLoS Comput Biol. 2010 Sep 23;6(9).

126. Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Deng MC, Cappola TP, Kao A, Anderson AS, Cotts WG, Ewald GA, Baran DA, Bogaev RC, Elashoff B, Baron H, Yee J, Valantine HA; IMAGE Study Group. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med. 2010 May 20;362(20):1890-900.

125. Haddad F, Deuse T, Pham M, Khazanie P, Rosso F, Luikart H, Valantine H, Leon S, Vu TA, Hunt SA, Oyer P, Montoya JG. Changing trends in infectious disease in heart transplantation. J Heart Lung Transplant. 2010 Mar;29(3):306-15.

124. Haddad F, Fisher P, Pham M, Berry G, Weisshaar D, Kuppahally S, Vrtovec B, Deuse T, Virani S, Fearon W, Valantine H, Hunt S. Right ventricular dysfunction predicts poor outcome following hemodynamically compromising rejection. J Heart Lung Transplant. 2009 Apr;28(4):312-9.

123. Khush KK, Valantine HA. New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. Review.

122. Deuse T, Haddad F, Pham M, Hunt S, Valantine H, Bates MJ, Mallidi HR, Oyer PE, Robbins RC, Reitz BA. Twenty-year survivors of heart transplantation at Stanford University. Am J Transplant. 2008 Sep;8(9):1769-74.

121. Sinha SS, Pham MX, Vagelos RH, Perlroth MG, Hunt SA, Lee DP, Valantine HA, Yeung AC, Fearon WF. Effect of rapamycin therapy on coronary artery physiology early after cardiac transplantation. Am Heart J. 2008 May;155(5):889.e1-6.

120. Potena L, Fearon WF, Sydow K, Holweg C, Luikart H, Chin C, Weisshaar D, Mocarski ES, Lewis DB, Valantine HA, Cooke JP. Asymmetric Dimethylarginine and Cardiac Allograft Vasculopathy Progression: Modulation by Sirolimus. Transplantation. 2008 Mar 27;85(6):827-833.

119. Zuckermann A, Manito N, Epailly E, Fiane A, Bara C, Delgado JF, Lehmkuhl H, Ross H, Eisen H, Chapman J, Valantine H. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant. 2008 Feb;27(2):141-9.

118. Chapman JR, Valantine H, Albanell J, Arns WA, Campistol JM, Eisen H, Frigerio M, Lehmkuhl H, Marcen R, Morris R, Nashan B, Pascual J, Pohanka E, Segovia J, Zuckermann A. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc. 2007 Dec;39(10):2937-


















50. Review.

117. Sakurai R, Yamasaki M, Nakamura M, Hirohata A, Honda Y, Bonneau HN, Luikart H, Yock PG, Fitzgerald PJ, Yeung AC, Valantine HA, Fearon WF. Determinants of lumen loss between years 1 and 2 after cardiac transplantation. Transplantation. 2007 Nov 15;84(9):1097-102.

116. Kuppahally SS, Valantine HA, Weisshaar D, Parekh H, Hung YY, Haddad F, Fowler M, Vagelos R, Perlroth MG, Robbins RC, Hunt SA. Outcome in cardiac recipients of donor hearts with increased left ventricular wall thickness. Am J Transplant. 2007 Oct;7(10):2388-95.

115. Pham MX, Deng MC, Kfoury AG, Teuteberg JJ, Starling RC, Valantine H. Molecular testing for long-term rejection surveillance in heart transplant recipients: design of the Invasive Monitoring Attenuation Through Gene Expression (IMAGE) trial. J Heart Lung Transplant. 2007 Aug;26(8):808-14.

114. Hirohata A, Nakamura M, Waseda K, Honda Y, Lee DP, Vagelos RH, Hunt SA, Valantine HA, Yock PG, Fitzgerald PJ, Yeung AC, Fearon WF. Changes in coronary anatomy and physiology after heart transplantation. Am J Cardiol. 2007 Jun 1;99(11):1603-7.

113. Fearon WF, Potena L, Hirohata A, Sakurai R, Yamasaki M, Luikart H, Lee J, Vana ML, Cooke JP, Mocarski ES, Yeung AC, Valantine HA. Changes in coronary arterial dimensions early after cardiac transplantation. Transplantation. 2007 Mar 27;83(6):700-5.

112. Potena L, Holweg CT, Vana ML, Bashyam L, Rajamani J, McCormick AL, Cooke JP, Valantine HA, Mocarski ES. Frequent occult infection with Cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis. J Clin Microbiol. 2007 Jun;45(6):1804-10.

111. Biadi O, Potena L, Fearon WF, Luikart HI, Yeung A, Ferrara R, Hunt SA, Mocarski ES, Valantine HA. Interplay between systemic inflammation and markers of insulin resistance in cardiovascular prognosis after heart transplantation. J Heart Lung Transplant. 2007 Apr;26(4):324-30.

110. Haddad F, Hunt SA, Perlroth M, Valantine H, Doyle R, Montoya J. Pulmonary nocardiosis in a heart transplant patient: case report and review of the literature. J Heart Lung Transplant. 2007 Jan;26(1):93-7.

109.

Tu W, Potena L, Stepick-Biek P, Liu L, Dionis KY, Luikart H, Fearon WF, Holmes TH, Chin C, Cooke JP, Valantine HA, Mocarski ES, Lewis DB. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation. 2006 Oct 10;114(15):1608-15.

108. Haddad F, Perez M, Fleischmann D, Valantine H, Hunt SA. Giant coronary aneurysms in heart transplantation: an unusual presentation of cardiac allograft vasculopathy. J Heart Lung Transplant. 2006 Nov;25(11):1367-70.

107. Cooke ME, Potena L, Luikart H, Valantine HA. Peripheral blood leukocyte counts in cytomegalovirus infected heart transplant patients: impact of acute disease versus subclinical infection. Transplantation. 2006 Dec 15;82(11):1419-24.

106. Starling RC, Pham M, Valantine H, Miller L, Eisen H, Rodriguez ER, Taylor DO, Yamani MH, Kobashigawa J, McCurry K, Marboe C, Mehra MR, Zuckerman A, Deng MC; Working Group on Molecular Testing in Cardiac Transplantation. Molecular testing in the management of cardiac transplant recipients: initial clinical experience. J Heart Lung Transplant. 2006 Dec;25(12):1389-95.

105. Haddad F, Hunt SA, Perlroth M, Valantine H, Doyle R, Montoya J. Pulmonary nocardiosis in a heart transplant patient: case report and review of the literature. J Heart Lung Transplant. 2007 Jan;26(1):93-7.

104. Fearon WF, Hirohata A, Nakamura M, Luikart H, Lee DP, Vagelos RH, Hunt SA, Valantine HA, Fitzgerald PJ, Yock PG, Yeung AC "Discordant Changes in Epicardial and Microvascular Coronary Physiology After Cardiac Transplantation: Physiologic Investigation for Transplant Arteriopathy II (PITA II) Study." J Heart Lung Transplant 2006; 25: 7: 765-771.

103. Potena L, Holweg CT, Chin C, Luikart H, Weisshaar D, Narasimhan B, Fearon WF, Lewis DB, Cooke JP, Mocarski ES, Valantine HA "Acute Rejection and Cardiac Allograft Vascular Disease Is Reduced by Suppression of Subclinical Cytomegalovirus Infection." Transplantation 2006; 82: 3: 398-405.

102. Ma IW, Valantine HA, Shibata A, Waskerwitz J, Dafoe DC, Alfrey EJ, Tan JC, Millan M, Busque S, Scandling JD "Validation of a screening protocol for identifying low-risk candidates with type 1 diabetes mellitus for kidney with or without pancreas transplantation." Clin Transplant 2006; 20: 2: 139-46

101. Kuppahally S, Al-Khaldi A, Weisshaar D, Valantine HA, Oyer P, Robbins RC, Hunt SA "Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients." Am J Transplant 2006; 6: 5: 986-92.


100. Kuppahally SS, Hunt SA, Valantine HA, Berry GJ. Recurrence of iron deposition in the cardiac allograft in a patient with non-HFE hemochromatosis. J Heart Lung Transplant. 2006 Jan;25(1):144-7.

99. Lehmkuhl H, Ross H, Eisen H, Valantine H. Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure. Transplant Proc. 2005 Dec;37(10):4145-9.

98. Ptaszek LM, Wang PJ, Hunt SA, Valantine H, Perlroth M, Al-Ahmad A. Use of the implantable cardioverter-defibrillator in long-term survivors of orthotopic heart transplantation. Heart Rhythm. 2005 Sep;2(9):931-3.

97. Chin C, Pittson S, Luikart H, Bernstein D, Robbins R, Reitz B, Oyer P, Valantine H. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Transplantation. 2005 Aug 27;80(4):477-81.

96. Valantine H. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial. J Heart Lung Transplant. 2005 Apr;24(4 Suppl):S191-5; discussion S210-1.

95. Eisen HJ, Kobashigawa J, Keogh A, Bourge R, Renlund D, Mentzer R, Alderman E, Valantine H, Dureau G, Mancini D, Mamelok R, Gordon R, Wang W, Mehra M, Constanzo MR, Hummel M, Johnson J; Mycophenolate Mofetil Cardiac Study Investigators. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005 May;24(5):517-25.

94. Kobashigawa JA, Tobis JM, Starling RC, Tuzcu EM, Smith AL, Valantine HA, Yeung AC, Mehra MR, Anzai H, Oeser BT, Abeywickrama KH, Murphy J, Cretin N. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol. 2005 May 3;45(9):1532-7.

93. Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant. 2004 May;23(5 Suppl):S187-93. Review.

92. Kato T, Chan MC, Gao SZ, Schroeder JS, Yokota M, Murohara T, Iwase M, Noda A, Hunt SA, Valantine HA.Glucose intolerance, as reflected by hemoglobin A1c level, is associated with the incidence and severity of transplant coronary artery disease. J Am Coll Cardiol. 2004 Mar 17;43(6):1034-41.

91. Shiba N, Chan MC, Kwok BW, Valantine HA, Robbins RC, Hunt SA. Analysis of survivors more than 10 years after heart transplantation in the cyclosporine era: Stanford experience. J Heart Lung Transplant. 2004 Feb;23(2):155-64.

90. Weis M, Kledal TN, Lin KY, Panchal SN, Gao SZ, Valantine HA, Mocarski ES, Cooke JP. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation. 2004 Feb 3;109(4):500-5.

89. Cantin B, Kwok BW, Chan MC, Valantine HA, Oyer PE, Robbins RC, Hunt SA. The impact of brain death on survival after heart transplantation: time is of the essence. Transplantation. 2003 Nov 15;76(9):1275-9.

88. Shiba N, Chan MC, Valantine HA, Gao SZ, Robbins RC, Hunt SA. Longer-term risks associated with 10-year survival after heart transplantation in the cyclosporine era. J Heart Lung Transplant. 2003 Oct;22(10):1098-106.

87. Eisen, Howard J.; Tuzcu, E. Murat; Dorent, Richard; Kobashigawa, Jon; Mancini, Donna; Valantine-von Kaeppler, Hannah A.; Starling, Randall C.; Sorensen, Keld; Hummel, Manfred; Lind, Joan M.; Abeywickrama, Kamal H.; Bernhardt, Peter. Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients. N. Eng. J. Med. 2003;349(9): 2003;847-858

86. Cantin B, Kwok BW, Shiba N, Valantine HA, Hunt SA, Chan MC. Post-operative conversion from cyclosporine to tacrolimus in heart transplantation: a single-center experience. J Heart Lung Transplant. 2003 Jul;22(7):723-30.

85. Cantin B, Giannetti N, Parekh H, Panchal SN, Kwok BW, Najem R, Woodman K, Hunt SA, Valantine HA. Mycophenolic acid concentrations in long-term heart transplant patients: relationship with calcineurin antagonists and acute rejection. Clin Transplant. 2002 Jun;16(3):196-201.

84. Cantin B, Zhu D, Wen P, Panchal SN, Dai X, Gwathmey JK, Reaven GM, Valantine HA. Reversal of diabetes-induced rat graft transplant coronary artery disease by metformin. J Heart Lung Transplant. 2002 Jun;21(6):637-43

83. Bostom AD, Brown RS Jr, Chavers BM, Coffman TM, Cosio FG, Culver K, Curtis JJ, Danovitch GM, Everson GT, First MR, Garvey C, Grimm R, Hertz MI, Hricik DE, Hunsicker LG, Ibrahim H, Kasiske BL, Kennedy M, Klag M, Knatterud ME, Kobashigawa J, Lake JR, Light JA, Matas AJ, McDiarmid SV, Miller LW, Payne WD,


Rosenson R, Sutherland DE, Tejani A, Textor S, Valantine HA, Wiesner RH. Prevention of post-transplant cardiovascular disease--report and recommendations of an ad hoc group. Am J Transplant. 2002 Jul;2(6):491-500.

82. Cantin B, Zhu D, Wen P, Panchal SN, Gwathmey JK, Reaven GM, Valantine HA. Preferential involvement of larger vessels in a rat model of diabetes-induced graft vasculopathy. J Heart Lung Transplant. 2002 Sep;21(9):1040-3.

81. Chan M.C.Y. Kwok B.W., Shiba N, Cantin B., Valantine H.A., Hunt S.A. Conversion of cyclosporine to tacrolimus for refractory of persistent myocardial rejection. Transplant Proc. 2002;34:000:1-5.

80. Blankenberg FG, Wen P, Dai M, Zhu D, Panchal SN, Tait JF, Post AM, Strauss HW, Valantine HA. Detection of early atherosclerosis with radiolabeled monocyte chemoattractant protein-1 in prediabeteic Zucker rats. Pediatr Radiol. 2001 Dec;31(12):827-35.

79. Valantine HA, Luikart H, Doyle R, Theodore J, Hunt S, Oyer P, Robbins R, Berry G, Reitz B. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation. 2001 Nov 27;72(10):1647-52.

78. Cantin B, Wen P, Zhu D, Dai M, Panchal SN, Billingham ME, Gwathmey JK, Valantine HA. Transplant coronary artery disease: a novel model independent of cellular alloimmune response. Circulation. 2001 Nov 20;104(21):2615-9.

77. Giannetti N, Herity NA, Alimollah A, Gao SZ, Schroeder JS, Yeung AC, Hunt SA, Valantine HA. Mild hyperhomocysteinemia is not associated with cardiac allograft coronary disease. Clin Transplant. 2001 Aug;15(4):247-52.

76. Chan MC, Giannetti N, Kato T, Kornbluth M, Oyer P, Valantine HA, Robbins RC, Hunt SA. Severe tricuspid regurgitation after heart transplantation. J Heart Lung Transplant. 2001 Jul;20(7):709-17.

75. Eisen HJ, Hobbs RE, Davis SF, Carrier M, Mancini DM, Smith A, Valantine H, Ventura H, Mehra M, Vachiery JL, Rayburn BK, Canver CC, Laufer G, Costanzo MR, Copeland J, Dureau G, Frazier OH, Dorent R, Hauptman PJ, Kells C, Masters R, Michaud JL, Paradis I, Renlund DG, Vanhaecke J, Mellein B, Mueller EA. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine--results at 24 months after transplantation. Transplantation. 2001 Jan 15;71(1):70-8.

74. Valantine H, Zhu D, Wen P, Panchal SN, Dai X. Impact of type 1 diabetes on microvascular vs. macrovascular involvement with TXCAD: is there a difference in models of the disease? J Heart Lung Transplant. 2001 Feb;20(2):186-187.

73. Valantine H, Rickenbacker P, Kemna M, Hunt S, Chen YD, Reaven G, Stinson EB. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study. Circulation. 2001 May 1;103(17):2144-52.

72. Eisen HJ, Hobbs RE, Davis SF, Laufer G, Mancini DM, Renlund DG, Valantine H, Ventura H, Vachiery JL, Bourge RC, Canver CC, Carrier M, Costanzo MR, Copeland J, Dureau G, Frazier OH, Dorent R, Hauptman PJ, Kells C, Master R, Michaud JL, Paradis I, Smith A, Vanhaecke J, Mueller EA, et al. Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine--results at six months after transplantation. Transplantation. 1999 Sep 15;68(5):663-71.

71. Valantine HA, Gao SZ, Menon SG, Renlund DG, Hunt SA, Oyer P, Stinson EB, Merigan T, Schroeder JS: Impact of prophylactic immediate post-transplant ganciclovir on development of transplant atherosclerosis: A post-hoc analysis of a randomized placebo-controlled study. Circulation 1999;100:61-66

70. Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H, Dureau G, Hershberger R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F, Valantine H for the Mycophenolate Mofetil Investigators: A randomized, active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 66(4):507-15;1998.

69. Hoang K, Chen YDI, Reaven G, Zhang LN, Ross H, Alpert S, Billingham M, Valantine H: Diabetes and dyslipidemia: A new model for transplant coronary artery disease. Circulation 97(21):2160-2168;1998.

68. Lopez FA, Crowley RS, Wastila L, Valantine HA, Remington JS: Scedosporium apiospermum


(Pseucallescheria boydii) investion in a heart transplant recipient: A case of mistaken identity. J Heart Lung Transplant 17;(3):321-4;1998.

67. Valantine HA, Reitz BA: Heart transplantation in the elderly. Transplant & Immunol Letter 13:5-7, March 1997.

66. Ross HJ, Gullestad L, Pak J, Slauson S, Valantine HA, Hunt SA: Methotrexate or total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: A comparative study. J Heart Lung Transplant 16:179-189, 1997.

65. Rickenbacher PR, Lewis NP, Valantine HA, Luikart H, Stinson EB, Hunt SA: Heart transplantation in patients over 54 years of age: Mortality, morbidity and quality of life. Eur Heart J 18:870-878, 1997.

64. Reichenspurner H, Gamberg P, Nitschke M, Valantine H, Hunt S, Oyer PE, Reitz BA: Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 29:627-628, 1997.

63. Gullestad L et al: Importance of decreased heart rate in predicting transplant coronary artery disease. Clin Transplant 11:628-632, 1997.

62. Ross HJ, Gullestad L, Hunt SA, Tovey DA, Puryear JB, McMillan A, Stinson EB, Valantine HA: Early Doppler echocardiographic dysfunction is associated with an increased mortality after orthotopic cardiac transplantation. Circulation 94(suppl II):II-289-293, 1996.

61. Kuo PC, Schroeder RA, Vagelos RH, Valantine H, Garcia G, Alfrey EJ, Haddow G, Dafoe DC: Volume-mediated pulmonary responses in liver transplant candidates. Clin Transplant 10 (6 pt 1):521-527, 1996.

60. Lewis N, Tsao P, Rickenbacher P, Haywood G, von der Leyen H, Cooke J, Hunt S, Billingham M, Valantine H, Fowler M: Induction of nitric oxide synthase in the human cardiac allograft is associated with contractile dysfunction of the left ventricle. Circulation 93:720-729, 1996.

59. Rickenbacher PR, Kemna MS, Pinto FJ, Hunt SA, Alderman EL, Schroeder JS, Stinson EB, Popp RL, Chen I, Reaven G, Valantine HA: Coronary artery intimal thickening in the transplanted heart: An in vivo intracoronary ultrasound study of immunologic and metabolic risk factors. Transplantation 61:46-53, 1996.

58. Lewis NP, Tsao PS, Rickenbacher PR, Xue C, Johns RA, Haywood GA, von der Leyen H, Trindade PT, Cooke JP, Hunt SA, Billingham ME, Valantine HA, Fowler MB: Induction of nitric oxide synthase in the human cardiac allograft is associated with contractile dysfunction of the left ventricle. Circulation 93:720-729, 1996.

57. Yeung AC, Davis SF, Hauptman PJ, Kobashigawa JA, Miller LW, Valantine HA, Ventura HO, Wiedermann J, Wilensky R, for the Multicenter Intravascular Ultrasound Transplant Study Group: Incidence and progression of transplant coronary artery disease over 1 year: Results of a multicenter trial with use of intravascular ultrasound. J Heart Lung Transplant 14:S215-S220, 1995.

56. Wagner JA, Ross H, Hunt S, Gamberg P, Valantine H, Merigan TC, Stinson EB: Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Transplantation 60:1473-1477, 1995.

55. Valantine HA: Role of lipids in allograft vascular disease: A multicenter study of intimal thickening detected by intravascular ultrasound. J Heart Lung Transplant 14:S234-237, 1995.

54. Rickenbacher PR, Pinto FJ, Lewis NP, Hunt SA, Alderman EL, Gamberg P, Schroeder JS, Hill I, Brown BW, Valantine HA: Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation. Circulation 92: 3445-3452, 1995.

53. Rickenbacher PR, Pinto FJ, Chenzbraun A, Botas J, Lewis NP, Alderman EL, Valantine HA, Hunt SA, Schroeder JS, Popp RL, Yeung AC: Incidence and severity of transplant coronary artery disease early and up to 15 years after transplantation as detected by intravascular ultrasound. J Am Coll Cardiol 25:171-177, 1995.

52. Rickenbacher PR, Pinto FJ, Lewis NP, Hunt SA, Gamberg P, Alderman EL, Schroeder JS, Valantine HA: Correlation of donor characteristics with transplant coronary artery disease as assessed by intracoronary ultrasound and coronary angiography. Am J Cardiol 76:340-345, 1995.

51. Miller L, Kobashigawa J, Valantine H, Ventura H, Hauptman P, O’Donnell J, Wiedermann J, Yeung A, and the Sandoz/CVIS Investigators: The impact of cyclosporine dose and level on the development and progression of allograft coronary disease. J Heart Lung Transplant 14:S227-S234, 1995.

50. Kuo PC, Alfrey EJ, Li K, Vagelos R, Valantine H, Garcia G, Dafoe DC: Magnetic resonance imaging-derived parameter of portal flow predicts volume-mediated pulmonary hypertension in liver transplant candidates.


Surgery 118:685-691, 1995.

49. Kuo PC, Luikart H, Busse-Henry S, Hunt SA, Valantine HA, Stinson EB, Oyer PE, Scandling JD, Alfrey EJ, Dafoe DC: Clinical outcome of interval cadaveric renal transplantation in cardiac allograft recipients. Clin Transplant 9:92-97, 1995.

48. Kobashigawa JA, Miller L, Yeung A, Hauptman P, Ventura H, Wilensky R, Valantine H, Wiedermann J, and the Sandoz/CVIS Investigators: Does acute rejection correlate with the development of transplant coronary artery disease? A multicenter study using intravascular ultrasound. J Heart Lung Transplant 14:S221-S226, 1995.

47. Deng MC, Bell S, Huie P, Pinto F, Hunt SA, Stinson EB, Sibley R, Hall BM, Valantine HA: Cardiac allograft vascular disease: Relationship to microvascular cell surface markers and inflammatory cell phenotypes on endomyocardial biopsy. Circulation 91:1647-1654, 1995.

46. Chenzbraun A, Pinto FJ, Alderman EL, Botas J, Oesterle SN, Schroeder JS, Valantine H, Popp RL: Distribution and morphologic features of coronary artery disease in cardiac allografts: An intracoronary ultrasound study. J Am Soc Echocardiogr 8:1-8, 1995.

45. Alpert S, Lewis NP, Ross H, Fowler M, Valantine HA: The relationship of granzyme A and perforin expression to cardiac allograft rejection and dysfunction. Transplantation 60: 1478-1485, 1995.

44. Wu CJ, Kurbegov D, Lattin B, Burchard E, Finkle C, Valantine H, Billingham ME, Starnes VA, Clayberger C: Cytokine gene expression in human cardiac allograft recipients. Transplant Immunol 2:199-207, 1994.

43. Valantine H, Johnson F, Dong C, Lewis N, Tovey D, Huie P, Pratt R, Stinson E, Hunt S, Sibley R: Cytokines as potential mediators of acute allograft diastolic dysfunction in cyclosporine-treated patients: A pilot study using in situ hybridization. Transplant Proc 26:2852-2853, 1994.

42. Valantine H, Hunt S, Gamberg P, Miller J, Luikart H: Impact of cyclosporine dose on long-term outcome after heart transplantation. Transplant Proc 26:2710-2712, 1994.

41. Sarris GE, Moore KA, Schroeder JS, Hunt SA, Fowler MB, Valantine HA, Vagelos RH, Billingham ME, Oyer PE, Stinson EB, Reitz BA, Shumway NE: Cardiac transplantation: The Stanford experience in the cyclosporine era. J Thor Cardiovasc Surg 108:240-252, 1994.

40. Pinto FJ, Chenzbraun A, Botas J, Valantine HA, St.Goar FG, Alderman EL, Oesterle SN, Schroeder JS, Popp RL: Feasibility of serial intracoronary ultrasound imaging for assessment of progression of intimal proliferation in cardiac transplant recipients. Circulation 90:2348-2355, 1994 .

39. Kramer MR, Valantine HA, Marshall SE, Starnes VA, Theodore J: Recovery of the right ventricle after single-lung transplantation in pulmonary hypertension. Am J Cardiol 73:494-500, 1994.

38. Kemna MS, Valantine HA, Hunt SA, Schroeder JS, Chen Y-D I, Reaven GM: Metabolic risk factors for atherosclerosis in heart transplant recipients. Am Heart J 128:68-72, 1994.

37. Collings CA, Pinto FJ, Valantine HA, Popylisen S, Puryear JV, Schnittger I: Exercise echocardiography in heart transplant recipients: A comparison with angiography and intracoronary ultrasonography. J Heart Lung Transplant 13:604-613, 1994.

36. Gao S-Z, Schroeder JS, Hunt S, Valantine H, Hill I, Stinson E: Influence of graft rejection on incidence of accelerated graft coronary artery disease: A new approach to analysis. J Heart Lung Transplant 2:1029-1035, 1993.

35. St.Goar FG, Pinto FJ, Alderman EL, Valantine HA, Schroeder JS, Gao S-Z, Stinson EB, Popp RL: Intracoronary ultrasound in cardiac transplant recipients: In vivo evidence of “angiographically silent” intimal thickening. Circulation 85:979-987, 1992.

34. Pinto FJ, St.Goar FG, Fischell TA, Stadius ML, Valantine HA, Alderman EL, Popp RL: Nitroglycerin-induced coronary vasodilation in cardiac transplant recipients. Circulation 85: 69-77, 1992.

33. Keogh AM, Valantine HA, Hunt SA, Schroeder JS, McIntosh N, Oyer PE, Stinson EB: Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant 11:892-901, 1992.

32. Kells CM, Marshall S, Kramer M, Hunt SA, Theodore J, Valantine HA, Starnes VA: Cardiac function after domino-donor heart transplantation: The Stanford experience. Am J Cardiol 69:113-116, 1992.

31. Valantine H, Keogh A, McIntosh N, Hunt S, Oyer P, Schroeder J: Cost containment: Coadministration of diltiazem with cyclosporine after heart transplantation. J Heart Lung Transplant 11:1-8, 1992.

30. Yeoh TK, Kramer M, Marshall S, Theodore J, Gibbons R, Valantine H, Starnes V: Changes in cardiac


morphology and function following single lung transplantation. Transplant Proc 23:1226-1227, 1991.

29. Valantine HA, Yeoh TK, Gibbons R, McCarthy P, Stinson E, Billingham ME, Popp R: Sensitivity and specificity of diastolic indices for rejection surveillance: temporal correlation with endomyocardial biopsy. J Heart Lung Transplant. 10:757-765, 1991.

28. Keogh A, Valantine H, Hunt S, Schroeder J, Oyer P: Increased rejection in gender mismatched graft-amelioration by triple therapy. J Heart Transplant 10:106-110, 1991.

27. Hosenpud JD, DeMarco T, Frazier OH, Griffith BP, Menkis AH, O’Connell JB, Olivari M-T, Valantine HA: Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation: Follow-up results of a multicenter survey. Circulation 84:III-338 - III-343, 1991.

26. DiBiase A, Tse T-M, Schnittger I, Wexler L, Stinson EB, Valantine HA: Frequency and mechanism of bradycardia in cardiac transplant recipients and need for pacemakers. Am J Cardiol 67:1385-1389, 1991.

25. Valantine HA, Hatle LK, Appleton CP, Gibbons R, Popp RL: Variability of Doppler echocardiographic indices of left ventricular filling in transplant recipients and normal subjects. J Am Soc Echocardiogr 3:276-284, 1990.

24. St.Goar FG, Gibbons R, Schnittger I, Valantine HA, Popp L: Left ventricular diastolic function: Doppler echocardiographic changes soon after cardiac transplantation. Circulation 82:872-878, 1990.

23. Masuyama T, Valantine HA, Gibbons R, Schnittger I, Popp RL: Serial measurement of integrated ultrasonic backscatter in human cardiac allografts for the recognition of acute rejection. Circulation 81:829-839, 1990.

22. Edwards BS, Hunt SA, Fowler MB, Valantine HA, Stinson EB, Schroeder JS: Cardiac transplantation in patients with preexisting neoplastic diseases. Am J Cardiol 65:501-504, 1990.

21. Valantine HA, Hunt SA, Fowler MB, Billingham ME, Schroeder JS: Frequency of familial nature of dilated cardiomyopathy and usefulness of cardiac transplantation in this subset. Am J Cardiol 63:959-963, 1989.

20. Valantine HA, Hunt SA, Billingham ME, Stinson EB, Popp RL: Increasing pericardial effusion in cardiac transplant recipients. Circulation 79:603-609, 1989.

19. Valantine HA, Billingham ME: Recurrence of amyloid in a cardiac allograft four months after transplantation. J Heart Transplant 8:337-341, 1989.

18. Valantine HA, Appleton CA, Hatle LK, Hunt SA, Billingham ME, Shumway NE, Stinson EB, Popp RL: A hemodynamic and Doppler echocardiographic study of ventricular function in long-term cardiac allograft recipients: Etiology and prognosis of restrictive-constrictive physiology. Circulation 79:66-75, 1989.

17. Heilbrunn SM, Shah P, Bristow MR, Ginsburg RA, Valantine HA, Fowler MB: Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during chronic metoprolol therapy. Circulation 79:483-490, 1989.

16. Gao SZ, Schroeder JS, Hunt SA, Billingham ME, Valantine HA, Stinson EB: Acute myocardial infarction in cardiac transplant recipients. Am J Cardiol 64:1093-1097, 1989.

15. Gao SZ, Schroeder JS, Alderman EL, Hunt SA, Valantine HA, Wiederhold V, Stinson EB: Prevalence of accelerated coronary artery disease in heart transplant survivors: Comparison of cyclosporine and azathioprine regimens. Circulation 80 (suppl III):III-100 to III-105, 1989.

14. Mannering D, Cripps T, Leech G, Mehta N, Valantine H, Gilmour S, Bennett ED: The dobutamine stress test as an alternative to exercise testing after acute myocardial infarction. Br Heart J 59:521-526, 1988.

13. Macoviak JA, Baldwin JC, Ginsburg R, Fowler M, Valantine H, Oyer PE, Stinson EB: Orthotopic cardiac transplantation for univentricular heart. Ann Thorac Surg 45:85-86, 1988.

12. Valantine HA, Tazelaar HD, Macoviak J, Mullin AV, Hunt SA, Fowler MB, Billingham ME, Schroeder JS: Transplantation for sarcoid heart disease. J Heart Transplant 6:244-250, 1987.

11. Valantine H, McKenna W, Nihoyannopoulos P, Mitchell A, Foale RA, Davies MJ, Oakley CM: Sarcoidosis: a pattern of clinical and morphological presentation. Br Heart J 57:256-263, 1987.

10. Valantine HA, Fowler MB, Hunt SA, Naasz C, Hatle LK, Billingham ME, Stinson EB, Popp RL: Changes in Doppler echocardiographic indices of left ventricular function as potential markers of acute cardiac rejection. Circulation 76 (suppl V):V86-V92, 1987.

9. Valantine H, Fowler M, Hatle L, Hunt S, Billingham M, Stinson E, Popp R: Doppler echocardiographic indices of diastolic function as markers of cardiac rejection. Transpl Proc 19:2556-2559, 1987.

8. Valantine HA, Appleton CA, Hatle L, Hunt SA, Stinson EB, Popp RL: Influence of recipient atrial contraction


on left ventricular filling dynamics of the transplanted heart assessed by Doppler echocardiography. Am J Cardiol 59:1159-1163, 1987.

7. Starnes VA, Stinson EB, Oyer PE, Valantine HA, Baldwin JC, Hunt SA, Shumway NE: Cardiac transplantation in children and adolescents. Circulation 76 (suppl V):V43-V47, 1987.

6. Mannering D, Bennett ED, Ward DE, Dawkins K, Dancy M, Valantine H, Mehta N: Accurate detection of triple vessel disease in patients with exercise induced ST segment depression after infarction. Br Heart J 57:133-138, 1987.

5. Nihoyannopoulos P, Venkatesan P, David J, Hackett D, Valantine H, Oakley CM: Left atrial myxoma: new perspectives in the diagnosis of murmur free cases. Br Heart J 56:554-560, 1986.

4. Dawee GSR, Valantine H, Cohen J: A case of meningococcal pericarditis. Commun Dis Rept, May 1985.

3. Bayley S, Valantine H, Bennett ED: The haemodynamic responses to incremental doses of nitroglycerine in left ventricular failure. Intensive Care Med 10:139-145, 1984.

2. Ward DE, Valantine H, Hui W: Occluded left main stem report of five patients and review of the published reports. Br Heart J 49:279, 1983.

1. Ward D, Valantine H: Spontaneous manifestations of dual AV nodal pathways resulting in complex patterns of AV conduction. Pacing Clin Electrophysiol 6:272-279,1983.

Invited Articles, Reviews and Perspectives (Most recent first) 35. Hopkins J, Fassiotto M, Ku MC, Mammo D, Valantine H. Designing a physician leadership development program based on effective models of physician education. Health Care Manage Rev. 2017 Feb 2. [Epub ahead of print] 34. Valantine HA. Science Has a Gender Problem. Sci Am. 2016 Nov 15;315(6):12. 33. PLOS Medicine Editors., Rid A, Johansson MA, Leung G, Valantine H, Burchard EG, Oh SS, Zimmerman C. Towards Equity in Health: Researchers Take Stock. PLoS Med. 2016;13(11):e1002186. 32. Valantine H. NIH's Essential 21st-Century Research Challenge: Enhancing Scientific Workforce Diversity. J Invest Dermatol. 2016;136(12):2327-2329. 31. Valantine HA, Lund PK, Gammie AE. A Systems Approach to Increasing the Diversity of the Biomedical Research Workforce. CBE Life Sci Educ. Fall 2016;15(3). pii: fe4. 30. Valantine HA. Advancing the Progress of Mentoring for Diversity in AIDS Research: Warming the Mentoring Climate. AIDS and Behavior 2016. Sep;20 Suppl 2:219-21. 29. Lauer M, Valantine H, Collins FS. Policy: NIH push to stop sexual harassment. Nature. 2016 Mar 3;531(7592):35. 28. National Institutes of Health addresses the science of diversity. Valantine HA, Collins FS. Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):12240-2. 27. Teaching corporate in college. Valantine HA, Beckerle MC, Reed KL, Towner D, Zahniser NR. Sci Transl Med. 2014 Aug 27;6(251):251fs33. 26. Beckerle MC, Reed KL, Scott RP, Shafer M-A, Towner D, Valantine HA, Zahniser NR. Medical Faculty Development: A Modern-Day Odyssey. Science Translational Medicine, 2011 Oct. 12; 3 (104) 25. Valantine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. J Heart Lung Transplant. 2007 Jun;26(6):557-64. 24. Potena L, Ferrara R, Mocarski ES, Lewis DB, Cooke JP, Grigioni F, Coccolo F, Magnani G, Fallani F, Magelli C, Valantine HA, Branzi A. Coronary allograft vasculopathy: pathophysiological interaction between the immune system, infections and metabolic syndrome. G Ital Cardiol (Rome). 2007 Feb;8(2):73-82. Review. 23. Potena L, Valantine HA. Cardiac allograft vasculopathy and insulin resistance--hope for new therapeutic targets. Endocrinol Metab Clin North Am. 2007 Dec;36(4):965-81. 22. Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, Naicker S, O'Connell P, Schnitzler M, Standl E, Torregosa JV, Uchida K, Valantine H, Villamil F, Vincenti F, Wissing M. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant. 2005 Jun;19(3):291-8. Review.


21. Eisen H, Kobashigawa J, Starling RC, Valantine H, Mancini D. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors. Transplant Proc. 2005 May;37(4 Suppl):4S-17S. Review. 20. Valantine H, Zuckermann A. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation. J Heart Lung Transplant. 2005 Apr;24(4 Suppl):S185-90; discussion S210-1. Review. 19. Valantine HA. The role of viruses in cardiac allograft vasculopathy. Am J Transplant. 2004 Feb;4(2):169-77. Review. 18. Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant. 2004 May;23(5 Suppl):S187-93. Review. 17. Potena L, Holweg C, Valantine HA, Mocarski ES. Cytomegalovirus and heart transplant atherosclerosis: a likely guilt hidden by weak proofs. Transplantation. 2004 Aug 27;78(4):631. 16. Hannah A. Valantine. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant “atheroma” [OVERVIEWS] Transplantation 2003; 76(6):891-899 15. Keeffe BG, Valantine H, Keeffe EB. Detection and treatment of coronary artery disease in liver transplant candidates. Liver Transpl. 2001 Sep;7(9):755-61. Review 14. Valantine H. Cytomegalovirus and allograft injury. Current opinion in organ transplantation. 2001;6:No.4:305-309. 13. Moore R, Hernandez D, Valantine H. Calcineurin inhibitors and post-transplant hyperlipidaemias. Drug Saf. 2001;24(10):755-66. 12. Valantine H. Neoral use in the cardiac transplant recipient. Transplant Proc. 2000 May;32(3A Suppl):27S-44S. Review 11. Valantine HA. Role of CMV in transplant coronary artery disease and survival after heart transplantation. Transpl Infect Dis. 1999;1 Suppl 1:25-30. Review. 10. Valantine HA, Prevention of Chronic Cardiac Allograft Rejection: Transplantation Proc. Volume 31, Issues 1-2 , 3 February 1999, Pages 1288-1289 9. Valantine HA: Individualizing Immunosuppression: Strategies for the Next Decade; Guest Editor: Transplantation Proc 29 (8A) Suppl: Dec 1997. 8. Valantine HA, Schroeder JS: HMG-CoA reductase inhibitors reduce transplant coronary artery disease and mortality: Evidence for antigen-independent mechanisms? (editorial) Circulation 96:1370-1373, 1997. 7. Valantine HA: Diabetic cardiomyopathy: Diagnosis, treatment, and prevention, p. 25-28. Summary and Conclusions, p. 31. In: Prevention, Early Diagnosis, and Treatment of Heart Disease in African-Americans: Focusing on Coronary Heart Disease, Diabetes, Hypertension, and Dyslipidemia. ABC Digest of Urban Cardiology 3 (No.4; suppl), 1996. 6. Valantine HA, Schroeder JS: Recent advances in cardiac transplantation. N Engl J Med 333:660-661, 1995. 5. Valantine HA: Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: Evidence for a beneficial effect of hyperimmune globulin. Transplant Proc 27, no. 5 (suppl 1):49-57, 1995. 4. Valantine HA: Cardiac allograft vascular disease: Pathophysiologic mechanisms leading to atherosclerosis. J Vasc Med Biol 5 (no. 5-6):233--245, 1994. 3. Valantine HA: Rejection surveillance by Doppler echocardiography (invited editorial). J Heart Lung Transplant 12:422-426, 1993. 2. Valantine HA, Pinto FJ, St.Goar FG, Alderman EL, Popp RL: Intracoronary ultrasound imaging in heart transplant recipients: The Stanford experience. J Heart Lung Transplant 11: S60-S64, 1992. 1. Valantine HA, Schroeder JS: Cardiac transplantation. Intensive Care Med 15:283-289, 1989 Book Chapters 7. Valantine HA: Long-term management and results in heart transplant recipients. In: Macoviak JA (ed). Cardiology Clinics. Philadelphia, WB Saunders, 1990, v.8. pp. 141-148. 6. Valantine H, Schroeder JS: Transplant coronary disease. In: Lewis BS, Kimshi A (eds). Heart Failure Mechanisms and Management. New York: Springer-Verlag, 1991, pp. 466-474.


5. Popp RL, Valantine H: Is ultrasound of clinical value in the management of heart transplant patient? In: Hanrath P et al. (ed). Cardiovascular Imaging by Ultrasound, ch. 6. The Netherlands: Kluwer Academic Publishers, 1992, pp. 61-70. 4. Valantine HA, Hunt SA: Clinical and non-invasive methods of diagnosing rejection after heart transplantation. In: Rose ML, Yacoub MH (ed). Immunology of Heart and Lung Transplantation. London: Edward Arnold, 1993, pp. 219-231.

3. Hunt SA, Valantine HA: Cardiac transplantation biology: Pharmacology and therapeutics. In: Singh BN, Dzau VJ, Vanhoutte PM, Woosley RL (eds). Cardiovascular Pharmacology and Therapeutics. New York: Churchill Livingstone, 1994, pp. 1091-1097. 2. Valantine HA, Schnittger I: Echocardiographic evaluation of the patient post-cardiac transplant: Role in identifying early rejection. In: Otto CM (ed). Clinical Echocardiography. Philadelphia, WB Saunders. 3rd Edition 1997. 1. Giannetti N, Valantine HA: Echocardiographic diagnosis of acute allograft rejection. In: Ballester M, Carrio I, Dec GW, Narula J (eds). Cardiac Allograft Rejection. Springer-Verlag, 1998

hannah a. valantine, m.d., m.r.c.p. - workforce … chelsea college, london university, uk b.sc.,...

Documents